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Methods For Survival Analysis In Small Samples
Abstract
Studies with time-to-event endpoints and small sample sizes are commonly seen; however, most statistical
methods are based on large sample considerations. We develop novel methods for analyzing crossover and
parallel study designs with small sample sizes and time-to-event outcomes. For two-period, two-treatment
(2x2) crossover designs, we propose a method in which censored values are treated as missing data and
multiply imputed using pre-specified parametric failure time models. The failure times in each imputed
dataset are then log-transformed and analyzed using ANCOVA. Results obtained from the imputed datasets
are synthesized for point and confidence interval estimation of the treatment-ratio of geometric mean failure
times using model-averaging in conjunction with Rubin's combination rule. We use simulations to illustrate
the favorable operating characteristics of our method relative to two other existing methods. We apply the
proposed method to study the effect of an experimental drug relative to placebo in delaying a symptomatic
cardiac-related event during a 10-minute treadmill walking test. For parallel designs for comparing survival
times between two groups in the setting of proportional hazards, we propose a refined generalized log-rank
(RGLR) statistic by eliminating an unnecessary approximation in the development of Mehrotra and Roth's
GLR approach (2001). We show across a variety of simulated scenarios that the RGLR approach provides a
smaller bias than the commonly used Cox model, parametric models and the GLR approach in small samples
(up to 40 subjects per group), and has notably better efficiency relative to Cox and parametric models in terms
of mean squared error. The RGLR approach also consistently delivers adequate confidence interval coverage
and type I error control. We further show that while the performance of the parametric model can be
significantly influenced by misspecification of the true underlying survival distribution, the RGLR approach
provides a consistently low bias and high relative efficiency. We apply all competing methods to data from two
clinical trials studying lung cancer and bladder cancer, respectively. Finally, we further extend the RGLR
method to allow for stratification, where stratum-specific estimates are first obtained using RGLR and then
combined across strata for overall estimation and inference using two different weighting schemes. We show
through simulations the stratified RGLR approach delivers smaller bias and higher efficiency than the
commonly used stratified Cox model analysis in small samples, notably so when the assumption of a constant
hazard ratio across strata is violated. A dataset is used to illustrate the utility of the proposed new method.
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ABSTRACT
METHODS FOR SURVIVAL ANALYSIS IN SMALL SAMPLES
Rengyi Xu
Pamela A. Shaw
Devan V. Mehrotra
Studies with time-to-event endpoints and small sample sizes are commonly seen; however, most
statistical methods are based on large sample considerations. We develop novel methods for an-
alyzing crossover and parallel study designs with small sample sizes and time-to-event outcomes.
For two-period, two-treatment (2×2) crossover designs, we propose a method in which censored
values are treated as missing data and multiply imputed using pre-specified parametric failure time
models. The failure times in each imputed dataset are then log-transformed and analyzed using
ANCOVA. Results obtained from the imputed datasets are synthesized for point and confidence
interval estimation of the treatment-ratio of geometric mean failure times using model-averaging in
conjunction with Rubin’s combination rule. We use simulations to illustrate the favorable operat-
ing characteristics of our method relative to two other existing methods. We apply the proposed
method to study the effect of an experimental drug relative to placebo in delaying a symptomatic
cardiac-related event during a 10-minute treadmill walking test. For parallel designs for comparing
survival times between two groups in the setting of proportional hazards, we propose a refined gen-
eralized log-rank (RGLR) statistic by eliminating an unnecessary approximation in the development
of Mehrotra and Roth’s GLR approach (2001). We show across a variety of simulated scenarios
that the RGLR approach provides a smaller bias than the commonly used Cox model, parametric
models and the GLR approach in small samples (up to 40 subjects per group), and has notably
better efficiency relative to Cox and parametric models in terms of mean squared error. The RGLR
approach also consistently delivers adequate confidence interval coverage and type I error control.
We further show that while the performance of the parametric model can be significantly influenced
by misspecification of the true underlying survival distribution, the RGLR approach provides a con-
sistently low bias and high relative efficiency. We apply all competing methods to data from two
clinical trials studying lung cancer and bladder cancer, respectively. Finally, we further extend the
iv
RGLR method to allow for stratification, where stratum-specific estimates are first obtained using
RGLR and then combined across strata for overall estimation and inference using two different
weighting schemes. We show through simulations the stratified RGLR approach delivers smaller
bias and higher efficiency than the commonly used stratified Cox model analysis in small samples,
notably so when the assumption of a constant hazard ratio across strata is violated. A dataset is
used to illustrate the utility of the proposed new method.
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CHAPTER 1
INTRODUCTION
Most statistical methods are developed based on large sample considerations. In real data applica-
tions, however, clinical trials and epidemiological studies with time-to-event outcomes do not always
meet the large sample size requirement due to various reasons. In fact, trials with small samples
are often encountered, due to reasons such as rarity of the disease and nature of the trial design
(e.g., an early phase or pilot clinical trial). Commonly used methods in a typical survival analysis
include Cox proportional hazards model (Cox, 1972) and parametric regression. Inference is typi-
cally based on large sample theory, and may not be appropriate under small samples. Crossover
trials also often have small samples, as every subject serves as his or her own control to help
achieve higher efficiency than parallel designs. However, there is a lack of existing methods for an-
alyzing crossover studies with time-to-event outcomes. We focus on three specific types of designs
with time-to-event response variables and small sample sizes: two-period two-treatment crossover
trials, two-group parallel designs in the setting of proportional hazards without stratification, and
two-group parallel designs with stratification and proportional hazards.
1.1. Background
1.1.1. Crossover Designs
Crossover designs compare treatment effects on the same subject over different treatment peri-
ods. For trials with limited recruitment, crossover designs are ideal to use for higher efficiency than
parallel designs. Under the commonly used two-period, two-treatment (2×2) crossover designs,
patients are randomized to one of two sequences, AB or BA, where A and B are the treatment
labels. A ‘washout’ period is included between the two periods to ensure no carry-over effects. The
use of a period-specific baseline measurement, which is taken before the subject is given the treat-
ment in each period, has been shown to increase statistical power (Chen, Meng, and Zhang, 2012;
Kenward and Roger, 2010; Senn, 2002). There are many existing methods for handling baseline
information in the analysis of crossover trials with continuous endpoints, including ignoring base-
line measurements, analyzing the change from baseline, using a function of the baselines as a
covariate, and joint-modeling of baseline and post-treatment responses (Chen, Meng, and Zhang,
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2012; Hills and Armitage, 1979; Kenward and Roger, 2010; Metcalfe, 2010; Yan, 2013). Some
recommended methods for providing higher efficiency than others include analysis of covariance
(ANCOVA) and joint-modeling of the within-subject difference in treatment responses and differ-
ence in baseline responses (Mehrotra, 2014). The commonly used method, analysis of the change
from baseline, suffered from poor efficiency, as also discussed by Kenward and Roger (2010) and
Metcalfe (2010).
All methods mentioned above are for continuous endpoints, but crossover trials with time-to-event
endpoints are also commonly encountered in research. Existing literature for examining treatment
differences in crossover trials with censored time-to-event endpoints includes both regression-
based and test-based approaches. France, Lewis, and Kay (1991) used stratified Cox regression,
where each subject was treated as a stratum. Feingold and Gillespie (1996) proposed an approach
based on the generalized Wilcoxon test. More recently, Brittain and Follmann (2011) proposed a
hierarchical rank (H-R) test, where each patient is assigned a rank based on whether and when he
or she has an event. The first ordering of the rank is determined by whether the individual has an
event during any of the two periods, and the second ordering of the rank is based on the times of
the events. A two-group Wilcoxon test is performed using the assigned ranks to test for the treat-
ment effect. Brittain and Follmann (2011) showed that the H-R test has similar or greater power
than both the Feingold and Gillespie’s method and stratified Cox method under certain censoring
patterns. However, none of these approaches utilizes baseline information, and whether and how
to utilize baseline information in crossover trials with time-to-event outcomes has not been studied.
1.1.2. Parallel Designs under Proportional Hazards without Stratification
In parallel designs with time-to-event outcomes comparing two treatment groups, the parameter of
interest is usually the hazard ratio, also referred to as relative risk. Under the proportional haz-
ards assumption, i.e., the hazard ratio is constant throughout time, it is conventional to use the
Cox proportional hazards model for estimation of relative risk and the log-rank test for hypothesis
testing (Cox, 1972). However, Cox regression is a large sample method, and may not provide an
appropriate result in small samples. Johnson et al. (1982) investigated the Cox model with one
binary indicator as the covariate, and found that in small samples, there are non-trivial differences
between the actual and asymptotic formula-based variances for the estimated log(hazard ratio).
Another commonly used method is parametric regression, but parametric models are subject to
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bias when the true underlying survival distribution is misspecified. Therefore, it is important to
study analysis methods for failure time data in small samples, which are quite common in real data
applications. Early phase clinical trials usually have less than 100 subjects per treatment group
(Pocock, 1983), and cancer trials might have limited recruitment as well if the disease is rare.
Mehrotra and Roth (2001) proposed a method based on a generalized log-rank (GLR) statistic for
the 2-group comparison to improve estimation and inference of hazard ratio in small sample studies.
They showed that even though asymptotically the GLR method has similar performance to the Cox
approach, when the sample size is small, GLR is notably more efficient than the Cox approach,
in terms of mean squared error (MSE) for the log relative risk when there are no tied event times.
A deficiency in the GLR method is that it uses an unnecessary approximation involving nuisance
parameters which contributes to bias in the estimated hazard ratio. Furthermore, estimation of the
nuisance parameters follows a non-intuitive path. These collectively offer opportunities to improve
the GLR method in a tangible way with practical benefits.
1.1.3. Parallel Designs with Stratification and Proportional Hazards
In parallel designs comparing two treatments, when the risk of having an event is known to be af-
fected by a prognostic factor, such as gender or race, stratification is employed in the design stage.
Subjects are first divided into each stratum based on his or her prognostic factor characteristics,
and then within each stratum, randomized to receive one of the treatments. The goal is estimation
and inference involving the true ‘overall’ hazard ratio, defined as the exponent of the weighted mean
of the stratum-specific true log hazard ratios using population relative frequency weights. Under the
assumption of proportional hazards in each stratum, stratified Cox model is used to analyze such
data. The stratified Cox model assumes that the hazard ratio is constant across strata, which is not
always true. If there exists a stratum-treatment interaction, the conventional stratified Cox model
tends to provide biased and less efficient results. Mehrotra, Su, and Li (2012) proposed a two-step
stratified Cox approach to allow for different hazard ratios across strata, and combine the stratum-
specific log hazard ratio by two weighting options, sample size weights and minimum risk weights
(Mehrotra and Railkar, 2000). The two-step analysis provides comparable power to the one-step
Cox analysis when there is no stratum-treatment interaction, but notably higher power when there
is an interaction. It also delivers a point estimator for the overall treatment effect with very small
bias. However, the Mehrotra, Su, and Li (2012) approach is based on large sample theory and
3
hence not ideal for small studies.
1.2. Novel Developments
In this dissertation, we focus on developing methods for analyzing studies with time-to-event out-
comes in small samples, and specifically in three settings: 2×2 crossover designs with baseline
measurements, parallel designs for two group comparison under proportional hazards without strat-
ification, and stratified parallel designs under proportional hazards.
In Chapter 2, we propose a regression-based method using multiple imputation (MI) of censored
event times in conjunction with analysis of covariance (ANCOVA) to incorporate baseline measure-
ments into the analysis of crossover studies with time-to-event outcomes. In the imputation step,
we propose to fit multiple candidate survival models, and use frequentist model averaging to pool
the final results. Unlike Bayesian model averaging (Bates and Granger, 1969; Raftery, Madigan,
and Hoeting, 1997), which requires setting a prior probability to each candidate model, frequentist
model averaging does not need any priors (Buckland, Burnham, and Augustin, 1997; Burnham and
Anderson, 2003; Hjort and Claeskens, 2003). The final point estimator is obtained by averaging
across the imputations and a variance estimator is created that accounts for the uncertainty from
both model averaging and imputation. We show that there can be a great efficiency gain in us-
ing baseline information for time-to-event endpoints in crossover trials, compared to H-R test and
stratified Cox model. Furthermore, our proposed method delivers a point and confidence interval
estimate with small-to-no-bias of the treatment-ratio of geometric mean event times.. We demon-
strate the impressive performance of our proposed method through simulation studies and apply it
to data from a crossover trial studying a new drug’s effect on delaying a symptomatic cardiac-related
event during a 10-minute treadmill walking test.
In Chapter 3, we focus on the parallel design for the two group comparison without stratification
and propose a refined GLR (RGLR) method by replacing the ‘approximate’ nuisance parameters
with ‘exact’ counterparts in the original GLR statistic. We develop the RGLR statistic for settings
with and without tied event times, and show through extensive simulations that our proposed RGLR
method provides notably smaller bias than GLR, Cox and parametric models, and provides a high
relative efficiency and adequate 95% confidence interval coverage rate. We also provide further
insights by developing an alternate and intuitive approach to estimate the nuisance parameter in
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the GLR statistic. Finally, we illustrate the method in two clinical trials studying lung cancer and
bladder cancer.
We further extend the RGLR method to allow for stratification factors in the analysis of a parallel two-
group design in Chapter 4. Instead of assuming a constant hazard ratio across all strata as done by
the commonly used stratified Cox model analysis, we allow the hazard ratio to vary across stratum,
and use two weighting schemes to combine the stratum-specific estimates of the log(hazard ratio).
We show through simulations that RGLR-based estimators provide smaller bias and higher relative
efficiency than both the conventional one-step and the two-step stratified Cox model estimator. We
apply the proposed method to a simulated data example for illustration.
We provide concluding remarks in Chapter 5 and discuss potential directions for future research.
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CHAPTER 2
INCORPORATING BASELINE MEASUREMENTS IN CROSSOVER TRIALS WITH
TIME-TO-EVENT ENDPOINTS
2.1. Introduction
Crossover designs are commonly seen in clinical trials to compare the treatment effects on the
same subject over different treatment periods. For trials with limited recruitment, crossover designs
are ideal to use for higher efficiency than parallel designs. The ability of each person to serve as
his or her own control also mitigates the influence of potential confounding factors. In commonly
used two-period, two-treatment (2 × 2) crossover designs, subjects are randomized to one of two
sequences, AB or BA, where A and B are the treatment labels. A ‘washout’ period is included
between the two periods to ensure no carry-over effects. The use of a period-specific baseline
measurement, which is taken before the subject is given the treatment in each period, is often con-
sidered. However, whether and how to use a baseline measurement is often challenging, given the
extra cost and the need to determine which statistical methods can be used to fully utilize the in-
formation from the baselines. For a 2×2 crossover trial, each subject has four responses: baseline
(i.e., pre-treatment) in period 1, post-treatment in period 1, baseline in period 2 and post-treatment
in period 2. There are many existing methods for handling baseline information in the analysis of
crossover trials with continuous endpoints, including ignoring baseline measurements, analyzing
the change from baseline, using a function of the baselines as a covariate, and joint-modeling of
baseline and post-treatment responses (Chen, Meng, and Zhang, 2012; Hills and Armitage, 1979;
Kenward and Roger, 2010; Metcalfe, 2010; Senn, 2002; Yan, 2013).
Mehrotra (2014) evaluated and compared 13 different methods for analyzing 2×2 crossover trials
to incorporate baseline measurements with continuous endpoints. Among all the competing meth-
ods, two methods were shown to have the highest efficiency: analysis of covariance (ANCOVA)
with the within-subject difference in baseline responses used as a covariate, and joint-modeling
of the within-subject difference in treatment responses and difference in baseline responses. The
commonly used method, analysis of the change from baseline, was shown to have poor efficiency,
as also discussed by Kenward and Roger (2010) and Metcalfe (2010).
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All methods mentioned above are for continuous endpoints, but crossover trials with time-to-event
endpoints are also commonly encountered in research. For example, blood thinners like Warafin
are important in preventing outcomes such as blood clots and stroke, but can also induce undesir-
able increases in bleeding time from simple cuts or other injuries. In this setting, researchers are
sometimes interested in studying the effect of an experimental anticoagulant drug on bleeding time
using a crossover design with a baseline measurement at the beginning of each period. Kimchi et
al. (1983) and Markman et al. (2015) both studied a drug’s effect in a crossover trial with a time-to-
event outcome and collected baseline meausurements. However, neither incorporated the baseline
information into their analysis. Our motivating data example is a crossover trial studying a drug’s
effect in preventing cardiac-related symptoms in a treadmill walking test. The outcome of interest
for each subject is time to a specific cardiopulmonary event, with the outcome recorded as ’>10
minutes’ (i.e., right censored) if the event has not yet occurred after 10 minutes of observation. Ex-
isting literature for examining treatment differences in crossover trials with censored time-to-event
endpoints includes both regression-based and test-based approaches. France, Lewis, and Kay
(1991) used a stratified Cox regression, where each subject was treated as a stratum. Feingold
and Gillespie (1996) proposed an approach based on the generalized Wilcoxon test. More recently,
Brittain and Follmann (2011) proposed a hierarchical rank (H-R) test, which they showed to have
similar or greater power than both the Feingold and Gillespie’s method and stratified Cox method
under certain censoring patterns. The main idea behind the H-R test is that avoiding an event is
more clinically meaningful than delaying an event. Therefore, each patient is assigned a rank that
orders how much better an individual does on the novel treatment. The first order of ranking is
based on whether patients have an event, and second order of ranking is based on the times of
the events. Patients who do not have an event on either treatment receive the same rank. With
assigned ranks for everyone, a two-group Wilcoxon test is then performed to test for a treatment
effect. However, none of these Wilcoxon-type approaches utilizes baseline information.
In this research, we propose a regression-based method using multiple imputation (MI) of cen-
sored values and analysis of covariance (ANCOVA) to incorporate baseline measurements into
the analysis of 2×2 crossover studies with censored time-to-event response outcomes. There is
often uncertainty about the true underlying survival distribution in real data applications, and mis-
specification of the distribution can lead to a biased point estimator and/or inefficient analysis. To
mitigate this issue, we propose to fit multiple survival models in the imputation step, and use fre-
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quentist model averaging to pool the final results from the ANCOVA step. Unlike Bayesian model
averaging (Bates and Granger, 1969; Raftery, Madigan, and Hoeting, 1997), which requires setting
a prior probability for each candidate model, frequentist model averaging does not require any pri-
ors (Buckland, Burnham, and Augustin, 1997; Burnham and Anderson, 2003; Hjort and Claeskens,
2003). To implement model averaging in the presence of multiple imputation, we need to account
for both the uncertainty from model averaging and imputation.
We show that there is a great efficiency gain in using baseline information for time-to-event end-
points in crossover trials compared to the H-R test and stratified Cox model. Furthermore, our
proposed method is also able to provide a point and confidence interval estimate of a meaningful
parameter of interest (treatment-ratio of geometric mean event times). Section 2.2 presents details
of the proposed method. In Section 2.3, we contrast the numerical performance of our proposed
method with that of the H-R test and stratified Cox model through simulation studies. Section 2.4 in-
cludes results from applying the different methods to our motivating real data example. Section 2.5
includes conclusions.
2.2. Methods
We consider a 2×2 crossover trial with two treatments, denoted by A and B. Subjects are random-
ized to either the AB or BA sequence, with a wash-out period between period 1 and 2. Let Xijk
and Yijk denote baseline and post-treatment event times, respectively, for subject j from sequence
k in period i, where i = 1, 2; j = 1, 2, . . . , n; and k = 1, 2. It is sufficient to assume that, after a
log transformation, (X1j1, Y1j1, X2j1, Y2j1)T and (X1j2, Y1j2, X2j2, Y2j2)T follow a multivariate dis-
tribution with different means and same variance-covariance structure Σ. We assume there is no
censoring at baseline, and in each period, subjects without a post-treatment event are censored at
the end of period, denoted by time τ .
We propose a three-step procedure using multiple imputation and ANCOVA to estimate the ratio
of geometric means of the event times for treatment A relative to B, denoted as θ, and test the
null hypothesis H0 : θ = 1. For distributions that are symmetric on the log scale, the geometric
mean is equivalent to the median. Thus, our parameter of interest can be used to approximate the
ratio of median survival of the two treatments, which is commonly of interest in survival analysis.
To implement our proposed method, we perform the following steps for each imputation iteration,
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details of which are given in the sub-sections below.
Step 1: Fit two candidate parametric event models, log-normal and Weibull, to impute the post-
treatment censored values sequentially, conditioning on the baseline event time in period 1 for
period 1 imputation, and both baseline event times and post-treatment event time in period 2 for
period 2 imputation.
Step 2: With the completed dataset from each candidate model, perform ANCOVA on the log-
transformed event times to estimate log θ and obtain its standard error.
Step 3: Average across the log θ estimates based on weights associated with Akaike information
criterion (AIC) from each parametric model fit to get a model averaged estimate and standard error,
and synthesize for overall point and confidence interval estimation across the multiply imputed
datasets using Rubin’s rule.
It is important to note that although we consider only two distributions in Step 1, our method can
be easily generalized to include more pre-specified candidate models in the imputation step. We
chose log-normal and Weibull because they are very flexible and in our experience provide rea-
sonable fitting models for capturing commonly seen event time data. Through numerical studies
in Section 2.3, we show that even averaging over a small number of models can deliver a good
performance.
2.2.1. Imputation
We generate M imputed data sets for each candidate model. Let Zijk = 0, 1 denote treatment A
and B, respectively for subject j in period i and sequence k. We impute the censored values in
period 1 first, and then impute the censored values in period 2. In the m-th imputed data set, we
use the baseline value in period 1 and treatment indicator, Z1jk, as covariates and fit two candidate
parametric survival models, log-normal and Weibull, respectively, to Y1jk.
log Y1jk = βs,0 + βs,1Z1jk + βs,2Us,1jk + σs,1Ws,1jk, (2.1)
where s = 1, 2 denotes the log-normal and Weibull model, respectively, Ws,1jk is the error dis-
tribution and Us,1jk is the baseline covariate in the s-th model. W1,1jk has the standard normal
distribution for the log-normal distribution and W2,1jk has the standard extreme value distribution
for the Weibull distribution. U1,1jk = logX1jk for the log-normal distribution, and U2,1jk = X1jk for
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the Weibull distribution; sample R code for implementation is provided in Appendix A. Equation (2.1)
is a representation of the log-normal and accelerated failure time (AFT) model framework for the
Weibull model that highlights the common linear regression model on the log-scale. For fitting the
parametric model, we analyze the log event times for the log-normal model and fit the traditional
Weibull model for the event times on the original scale. We use robust sandwich standard errors in
both candidate models to correct for potential model misspecification.
Let βˆs = (βˆs,0, βˆs,1, βˆs,2, σˆs,1)T and Σˆs denote the estimated coefficients and variance-covariance
matrix in the s-th candidate model, respectively. We draw βˆ
∗
s from a multivariate normal distribution
N(βˆs, Σˆs). For subject with a censored post-treatment value, we then impute a right-censored
value with an uncensored value by using βˆ∗s , treatment indicator Z1jk and subject-specific period 1
baseline values in equation (2.1). The corresponding uncensored post-treatment values in period
1 are denoted by Y (m)s,1jk.
Now, with complete data in period 1, we can then use the observed/imputed post-treatment values
in period 1, baseline values in both period 1 and period 2 as covariates, to impute post-treatment
censored values in period 2 by fitting the s-th model,
log Y2jk = αs,0 + αs,1Z2jk + αs,2Us,1jk + αs,3Vs,2jk + αs,4R
(m)
s,1jk + σs,2Ws,2jk, (2.2)
where U1,1jk = logX1jk, V1,2jk = logX2jk, R
(m)
s,1jk = log Y
(m)
s,1jk for log-normal distribution, and
U1,1jk = X1jk, V2,2jk = X2jk, R
(m)
s,1jk = Y
(m)
s,1jk for Weibull distribution, and Z2jk is the treatment
indicator in period 2.
The imputation procedure described above for period 1 is now implemented using random draws
from the assumed multivariate normal distribution of the vector of estimated regression coefficients
in equation (2.2) for each of the two parametric models. The corresponding uncensored post-
treatment values in period 2 are denoted by Y (m)s,2jk.
2.2.2. ANCOVA
After each imputation, we have two sets of complete data on every subject from the two candidate
models, log-normal and Weibull. Each imputed dataset is analyzed using ANCOVA on the log-
transformed event times. Specifically, we regress the difference between post-treatment event
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times, ∆(m)s,jk = log Y
(m)
s,1jk − log Y (m)s,2jk on the difference between baseline measurements, Djk =
logX1jk − logX2jk and the sequence indicator Qj .
∆
(m)
s,jk = γs,0 + γs,1Djk + γs,2Qj + s,jk, (2.3)
where s,jk ∼ N(0, η2).
The point estimator from the s-th model in the m-th imputed data set is log θˆ(m)s = γˆ
(m)
s,2 /2, which
is the logarithm of the ratio of geometric means for treatment A relative to B. The corresponding
variance estimate for log θˆ(m)s from the s-th model in the m-th imputed data set is vˆ
(m)
s .
2.2.3. Model Averaging and Rubin’s Combination Rule
For overall estimation and inference, we first combine the two estimators from the candidate mod-
els in each imputed data set, then pool the model-averaged estimators from all the imputed data
sets and obtain the pooled variance estimate that accounts for both the uncertainty from model
averaging and imputation (Schomaker and Heumann, 2014).
For model averaging, we need to assign a standardized weight. There are many different options
for the choice of weights, including an information criterion (Buckland, Burnham, and Augustin,
1997), Mallows’ criterion (Hansen, 2007; Mallows, 1973) and cross-validation criterion (Hansen
and Racine, 2012). We propose to use the straightforward and commonly used Akaike Information
Criterion (AIC) (Akaike, 1974) to assign weights. Let Is denote the AIC for the ANCOVA regression,
equation (3), from the s-th candidate model, then the weight is defined as (Buckland, Burnham, and
Augustin, 1997)
ws =
exp(−Is/2)∑2
i=1 exp(−Ii/2)
.
The model averaged estimator in the m-th imputed data set is log θˆ(m) =
∑2
s=1 ws log θˆ
(m)
s , and
the variance for the model averaging estimator is estimated by (Buckland, Burnham, and Augustin,
1997)
Vˆar(log θˆ(m)) =
[
2∑
s=1
ws
√
Vˆar(log θˆ(m)s ) + (log θˆ
(m)
s − log θˆ(m))2
]2
. (2.4)
Now, we can pool the model averaged estimators across the M imputed data sets, with the final
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estimator calculated as (Schomaker and Heumann, 2014)
log
¯ˆ
θ =
1
M
M∑
m=1
log θˆ(m). (2.5)
When there is no model averaging, we can use Rubin (1987) to combine the results from multiple
imputation. As noted earlier, with the presence of model averaging, the uncertainty from both model
averaging and imputation needs to considered. The between-imputation variance is
vbtw =
1
M − 1
M∑
m=1
(log θˆ(m) − log ¯ˆθ)2.
The within-imputation variance is the average of the estimated variance from equation (4) across
M imputed data sets
vwithin =
1
M
M∑
m=1
Vˆar(log θˆ(m)).
Therefore, the total variance of the estimator after multiple imputation is (Schomaker and Heumann,
2014)
vtotal =
M + 1
M(M − 1)
M∑
m=1
(log θˆ(m)−log ¯ˆθ)2+ 1
M
M∑
m=1
[
2∑
s=1
ws
√
Vˆar(log θˆ(m)s ) + (log θˆ
(m)
s − log θˆ(m))2
]2
.
(2.6)
To test the null hypothesis H0 : θ = θ0 (with θ0 = 1 in our application), we carry out a t-test with
test statistic (log ¯ˆθ − log θ0)/√vtotal. To calculate the degrees of freedom d∗ for the t-test, we follow
Barnard and Rubin (1999) so that d∗ = (1/d+ 1/dˆobs)−1, where d = (M − 1)[1 + vwithin(1+1/M)vbtw ]2 and
dˆobs = (1− (1 + 1/M)vbtw/vtotal)(dcom+1dcom+3 )dcom, and dcom is the degrees of freedom for
¯ˆ
θ when there
are no missing values.
2.3. Simulation
2.3.1. Simulation Set-up
To compare the performance of our proposed approach to the H-R test and stratified Cox model,
we carried out a simulation study to examine type I error and power among all three methods.
Since our method utilized baseline information, we also included the period-specific baseline event
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times, in addition to the treatment indicator, as covariates in the stratified Cox model to make a
fair comparison. The H-R test, however, does not incorporate baseline information, and thus, we
used the method as is. We also examined the bias and 95% confidence interval (C.I.) coverage
probability from our proposed estimator; of note, the other two methods cannot deliver an estimate
of our parameter of interest (θ).
We simulated three underlying distributions for event times, namely log-normal, exponential and
gamma. Two of the distributions, log-normal and exponential (a special case of the Weibull),
are included in the candidate models in our method, while the gamma distribution is not. The
density curves for each of the three distributions are shown in Supplementary Figure A.1 in Ap-
pendix A. Under the log-normal distribution, for each of the N subjects in sequence AB and BA,
we generated correlated log event times from a multivariate normal distribution with mean param-
eter (0, log θ, 0, 0)T for AB sequence and (0, 0, 0, log θ)T for BA sequence and common variance-
covariance structure with common variance 1 and correlation coefficients ρ12, ρ13, ρ14, ρ23, ρ24, ρ34.
We considered three correlation structures, compound symmetry (CS), first-order autoregressive
(AR(1)), and equipredictability (EP), where ρ12 = ρ13 = ρ14 = ρ23 = ρ24 = ρ34 = ρ for CS,
ρ12 = ρ23 = ρ34 = ρ, ρ13 = ρ24 = ρ
2, ρ14 = ρ
3 for AR(1), and ρ23 = ρ14, ρ24 = ρ13, ρ34 = ρ12 for EP.
The correlation structures are as follows:
ΣCS =

1 ρ ρ ρ
ρ 1 ρ ρ
ρ ρ 1 ρ
ρ ρ ρ 1

ΣAR =

1 ρ ρ2 ρ3
ρ 1 ρ ρ2
ρ2 ρ 1 ρ
ρ3 ρ2 ρ 1

ΣEP =

1 ρ12 ρ13 ρ14
ρ12 1 ρ14 ρ13
ρ13 ρ14 1 ρ12
ρ14 ρ13 ρ12 1

.
We assumed no censoring in baseline event times in each period, and the post-treatment event
times were right-censored at time τ . As discussed in the previous section, the parameter of interest
θ is the ratio of the geometric means of the event times for treatment A and treatment B, and under
the log-normal distribution, it is equivalent to the ratio of median event times.
For the exponential distribution, we used copulas (Sklar, 1973) to generate correlated event times
from a multivariate exponential with mean (2, 2θ, 2, 2)T for AB sequence and (2, 2, 2, 2θ)T for BA se-
quence and common variance-covariance structure and correlation coefficients as specified above.
Note that the ratio of arithmetic means is equivalent to the ratio of geometric means under expo-
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nential distribution. Since copulas only preserves the rank correlation coefficient but not the linear
correlation coefficient (Genest and MacKay, 1986), the correlated exponential data follows approx-
imately, but not exactly, the specified variance-covariance structure.
To further illustrate the performance of our proposed method, we also considered an underlying
gamma distribution, which is not included in our two candidate models from the imputation step.
Specifically, we used a gamma distribution with scale of 0.7 and shape of 2 for subjects in treat-
ment B. Event times for subjects in treatment A was generated from a gamma distribution with
scale of 0.7θ and shape of 2. We again used copulas to generate the correlated event times.
For AB sequence, the simulated event times followed a multivariate gamma distribution with mean
(1.4, 1.4θ, 1.4, 1.4)T , and for BA sequence, the event times follows a gamma distribution with mean
(1.4, 1.4, 1.4, 1.4θ)T . Note that it can be shown that the ratio of arithmetic means is equivalent to the
ratio of geometric means in the setting that event times in treatment A and B follow a gamma distri-
bution with the same shape parameter and ratio of scale parameter of θ. Again, the event times in
the two sequences followed a common variance-covariance structure and correlation coefficients
as specified above.
We varied the sample size, percentage of censoring, θ, correlation structure, and compared the
performance of the different methods. Sample size per sequence was varied as N = 12, 24, 48,
and percentage of censoring was controlled by changing the time τ , to generate 10% and 50%
censoring for the total sample.
The mean pairwise correlation coefficient ρ¯ took values of 0.5 and 0.7. Under CS, ρ = ρ¯. For AR(1),
ρ = 0.7 for ρ¯ = 0.5 and ρ = 0.83 for ρ¯ = 0.7. For EP, we set ρ12 = 0.6, ρ13 = 0.5, ρ12 = 0.4 when
ρ¯ = 0.5, and ρ12 = 0.8, ρ13 = 0.7, ρ12 = 0.6 when ρ¯ = 0.7. We generated M = 50 imputed datasets
within each of the 5000 replications. Under the null hypothesis, θ = 1. Under the alternative
hypothesis, we chose a value of θ such that the power was about 80% for the H-R test, given the
true underlying distribution, Σ, ρ¯ and percentage censoring.
2.3.2. Simulation Results
Table 2.1 reports type I error for the three distributions for the H-R test, stratified Cox model with
baseline adjustment and our proposed multiple imputation and model averaging and ANCOVA
method. As shown in Table 2.1, the stratified Cox model analysis had non-converge (NC) issues
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under several scenarios when the sample size was 12 and 24 subjects per sequence with 50%
censoring, and had an inflated type I error when there were 24 subjects per sequence with 10%
censoring, ρ¯ = 0.5 and CS structure under exponential distribution. When the true distribution was
gamma, the stratified Cox model analysis was associated with inflated type I error under CS struc-
ture with 24 subjects per sequence and ρ¯ = 0.7, 10% censoring, and with 48 subjects per sequence
and ρ¯ = 0.7, 50% censoring. The H-R test and our proposed model averaging method controlled
type I error throughout all the scenarios considered. Table 2.1 also reports the bias in the estimate
of log θ using our proposed method under the null hypothesis. The bias was negligible under all
simulated scenarios.
Figures 2.1, 2.2 and 2.3 show the power for the three different methods for N = 24 subjects per
sequence and different combinations of percentage censoring and variance-covariance structure
under the log-normal, exponential and gamma distributions, respectively; results for other sample
sizes are provided in Appendix A.
As shown in Figure 2.1, when the true distribution was log-normal, our proposed method always
provided a higher or similar power than the H-R test and stratified Cox model. For cases where the
H-R test or stratified Cox failed to deliver 80% power, our method was able to achieve power close
to or above 80%. The increase in power using our method was more significant under AR(1) and
EP structures than under CS structure. The power gain compared to the H-R test likely comes from
the fact that the H-R test fails to utilize baseline information. Likewise, our proposed method has a
substantially higher power than the stratified Cox model that adjusts for baseline covariates in part
because our method makes better use of the baseline information. In addition, the model averaging
aspect provides the flexibility of assuming more than one distribution and further improves the
efficiency of the analysis. Results from assuming only one distribution, either log-normal or Weibull,
is more prone to model misspecification in the imputation step.
Figure 2.2 displays the results when the true distribution was exponential. In this case, the true
variance-covariance structure and percentage censoring affected the relative performance of the
considered methods. When the true structure was CS, H-R test delivered higher power than the
other considered methods. Of note, CS structure usually does not capture the true correlation
pattern in most real data examples, since it assumes equal correlation among all pairs of with-
subject event times, which has low plausibility. When the true structure was AR(1) or EP, which
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are a more realistic representation of the correlation structure in real data applications, our method
again showed a substantial power gain compared to the H-R test and stratified Cox model under
50% censoring. When the percentage censoring was 10%, our method delivered similar power
as the H-R test. For all the other scenarios, where the stratified Cox model did not have non-
convergence issues, our proposed method was consistently more powerful than the stratified Cox
model.
Finally, when the underlying distribution was gamma, our proposed method still provided higher
power than the stratified Cox model throughout all scenarios, but slightly lower power than the H-R
test under CS structures, as shown in Figure 2.3. Under AR and EP structures, using multiple
imputation, model averaging and ANCOVA approach delivered a more efficient analysis than both
the H-R test and stratified Cox model. Recall that the true distribution, gamma, is not included
as one of the candidate models in the imputation step; however, we are still able to provide a
comparably efficient result. Additionally, our proposed method is able to provide a point and CI
estimate of the treatment effect, while the other two methods do not.
Table 2.2 reports percentage bias and 95% C.I. coverage probability for log θ using our proposed
method under the alternative hypothesis. Our method was able to control bias within 10% under
log-normal and exponential distribution. When the true distribution was gamma, it controlled bias
within 10% under 10% censoring, and under 50% censoring, bias was no larger than 11%. Impor-
tantly, the 95% C.I. coverage probability was maintained at or above the nominal level under all the
scenarios considered.
2.4. Data Application
We apply the three methods considered to a 2×2 crossover clinical trial of an investigation drug.
The trial recruited 40 subjects in total, and randomly assigned 20 to the placebo then drug sequence
and 20 to the drug then placebo sequence. The outcome variable was time until a symptomatic
cardiac-related event of interest during a 10-minute treadmill walking test. Each subject also had a
measurement at baseline before taking the treatment. Figure 2.4 displays the Kaplan-Meier curves
for post-treatment event times for placebo and drug in period 1 and period 2, separately.
The H-R test delivers a p-value of 0.052, indicating that there is not enough evidence at the two-
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Table 2.1: Type I error (target=5%) for the hierarchical rank test (H-R), stratified Cox model with
baseline adjustment (SCB) and proposed multiple imputation with model averaging and ANCOVA
(MIMA) for log-normal, exponential and gamma distributions under the null hypothesis H0 : θ = 1
and bias in the estimate of log θ using the proposed method (5000 simulations).
ρ = 0.5 ρ = 0.7
10% Censoring 50% Censoring 10% Censoring 50% Censoring
Distribution Σ
XXXXXXXXXXMethod
N/seq 12 24 48 12 24 48 12 24 48 12 24 48
Log-normal CS H-R 4.6 4.3 4.9 4.4 4.3 4.8 4.5 5.0 4.3 4.6 4.8 4.8
SCB 4.5 4.4 4.9 NC 4.4 4.6 4.5 5.0 4.8 NC 4.5 4.9
MIMA 4.3 4.8 4.9 2.4 3.9 4.9 4.8 4.9 4.8 1.9 3.8 4.2
Bias -0.002 -0.002 0.000 0.001 0.002 -0.002 0.005 -0.002 -0.001 0.001 0.003 0.002
AR(1) H-R 5.0 4.0 4.8 5.0 4.7 4.8 4.7 4.8 5.0 4.8 4.6 4.8
SCB 4.2 4.4 4.5 NC 4.6 4.9 3.6 4.2 5.1 NC 4.6 4.7
MIMA 4.6 4.4 4.7 2.8 3.8 4.8 4.7 4.7 5.0 2.6 4.0 4.5
Bias 0.002 0.002 0.001 -0.007 0.000 -0.002 -0.001 -0.002 0.001 0.001 -0.002 -0.001
EP H-R 4.4 5.1 4.7 4.8 4.4 4.4 4.8 4.3 4.4 4.4 5.1 4.9
SCB NC 4.9 4.5 NC 4.7 4.6 NC 3.7 4.3 NC NC 4.8
MIMA 4.5 5.0 5.0 2.7 4.4 4.7 4.7 4.4 4.7 1.4 3.2 3.7
Bias -0.001 0.001 -0.002 0.001 0.001 0.001 0.001 -0.001 0.001 0.002 -0.000 0.002
Exponential CS H-R 4.8 4.8 5.0 4.9 4.5 4.8 4.7 4.6 5.0 4.1 4.3 4.3
SCB 5.1 (5.6) 4.6 NC 4.7 5.0 4.0 4.7 5.3 NC 4.4 5.0
MIMA 4.7 5.0 4.4 2.2 3.8 5.1 4.4 4.8 4.5 1.8 2.9 4.0
Bias -0.003 -0.002 0.001 -0.071 -0.006 0.002 0.001 -0.001 0.002 0.063 0.002 -0.002
AR(1) H-R 4.6 4.6 4.6 4.6 5.0 4.4 4.3 5.0 5.1 4.5 4.5 4.8
SCB NC 4.5 5.2 NC 4.7 4.6 NC 4.8 5.2 NC NC 4.7
MIMA 4.9 4.7 4.2 2.0 3.5 4.2 4.4 4.5 4.5 1.9 2.9 3.0
Bias -0.001 0.004 0.002 0.002 0.001 0.002 -0.001 -0.002 0.002 0.004 -0.001 -0.003
EP H-R 4.2 4.3 4.4 4.5 4.2 4.4 4.8 4.7 4.9 4.4 4.5 4.9
SCB NC 4.4 4.8 NC 4.3 4.5 NC NC 4.2 NC NC 4.2
MIMA 4.4 4.3 4.5 1.8 3.3 4.3 4.4 4.6 4.6 1.4 2.1 2.4
Bias -0.004 0.001 0.001 0.003 0.003 -0.001 0.002 -0.001 0.001 -0.015 0.001 0.001
Gamma CS H-R 4.2 4.4 4.7 4.4 4.4 4.6 4.2 4.7 4.4 4.1 4.8 5.1
SCB 4.2 4.9 4.6 NC 4.6 4.8 NC (5.9) 4.7 NC 4.9 (5.6)
MIMA 4.5 4.7 4.9 4.2 4.7 5.0 4.7 5.0 4.8 3.2 4.4 4.8
Bias 0.001 0.002 -0.002 0.001 -0.000 0.001 0.002 0.002 -0.000 -0.002 -0.003 0.002
AR(1) H-R 4.3 4.6 4.4 4.7 5.1 4.5 4.4 4.2 4.3 4.3 4.7 4.8
SCB 3.7 5.1 4.8 NC 4.1 4.5 NC 4.6 4.1 NC 4.1 5.1
MIMA 4.7 5.1 4.6 3.8 4.6 4.7 4.9 4.7 4.1 3.3 4.6 4.6
Bias -0.000 -0.000 -0.001 -0.006 0.001 0.000 -0.001 0.001 0.001 0.001 0.000 0.001
EP H-R 4.9 4.6 5.2 4.7 4.5 4.6 4.7 4.2 4.7 4.6 5.1 4.4
SCB 4.3 5.0 5.2 NC 4.4 4.5 NC 3.8 5.0 NC 3.7 4.8
MIMA 4.7 4.3 4.9 3.5 4.7 5.0 4.8 4.7 4.5 3.0 3.9 4.0
Bias 0.000 0.001 0.001 0.003 -0.000 -0.003 -0.000 -0.001 -0.001 0.001 -0.000 -0.001
Type I error more than Z0.975 standard errors above 5% level is in parentheses. NC: non convergence. CS: compound symmetry covariance structure. AR(1): first-order
autoregressive covariance structure. EP: equipredicability covariance structure. ρ¯: mean pairwise correlation.
tailed 5% level of significance to show a difference between the drug and placebo in delaying the
event of interest. On the other hand, stratified Cox model adjusting for period-specific baseline and
our proposed method deliver a p-value of 0.020, and 0.005, respectively. The ratio of geometric
mean of time to the cardiac-related event for patients taking the drug to patients on placebo was
estimated to be 1.67, with 95% C.I of (1.18, 2.35). The raw data from this trial are provided in
Table 2.3, and R code used to generate the analysis results for all the three methods are provided
in Appendix A.
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Table 2.2: Percentage bias and 95% C.I. coverage probability under the alternative hypothesis
H1 : θ 6= 1 for the estimate of log θ using the proposed method under log-normal, exponential and
gamma distributions (5000 simulations).
ρ = 0.5 ρ = 0.7
10% Censoring 50% Censoring 10% Censoring 50% Censoring
Distribution Σ
XXXXXXXXXXMethod
N/seq 12 24 48 12 24 48 12 24 48 12 24 48
Log-normal CS %Bias -4.9 -4.7 -3.2 -8.6 -7.9 -7.2 -4.1 -3.3 -4.0 -8.0 -8.3 -9.5
Coverage 95.3 94.0 94.3 95.6 94.4 94.4 95.3 94.8 95.1 96.6 95.0 94.9
AR(1) %Bias -4.5 -4.0 -4.1 -9.4 -8.2 -8.5 -2.2 -2.3 -2.5 -5.5 -6.1 -5.5
Coverage 95.2 94.9 94.6 95.4 94.7 94.4 95.2 95.3 94.5 96.8 95.8 95.4
EP % Bias -4.6 -4.8 -3.5 -9.3 -8.1 -7.3 -2.0 -5.0 -2.2 -5.5 -5.1 -5.7
Coverage 95.1 94.8 94.7 96.1 94.4 94.4 95.8 96.5 95.3 97.8 96.8 96.0
Exponential CS %Bias 2.1 1.1 -0.1 1.4 0.8 0.8 1.7 1.3 0.9 2.4 2.7 3.3
Coverage 95.0 95.2 94.7 97.0 95.3 95.1 95.0 95.3 94.2 96.6 96.2 95.6
AR(1) %Bias 0.6 1.8 0.4 2.2 3.1 2.9 1.4 1.2 1.3 3.9 5.9 5.7
Coverage 94.8 94.9 95.2 96.3 95.7 95.4 94.9 95.3 95.1 97.1 96.3 95.7
EP %Bias 1.9 0.9 -0.1 1.5 1.8 1.4 1.8 1.7 2.4 3.6 4.1 4.1
Coverage 95.3 95.2 94.8 96.6 95.1 95.0 95.1 95.2 95.0 97.5 97.0 97.1
Gamma CS %Bias -5.4 -3.8 -3.6 -8.5 -3.3 -4.2 -3.9 -3.8 -3.0 -11.5 -5.1 -3.8
Coverage 95.0 94.9 95.0 94.9 94.7 94.6 95.0 95.6 95.3 94.8 95.5 94.8
AR(1) %Bias -5.2 -3.9 -3.3 -7.0 -4.8 -4.6 -3.7 -2.6 -1.7 -10.4 -10.6 -10.0
Coverage 95.0 94.6 95.0 95.5 94.5 94.7 95.2 94.9 95.4 95.1 94.6 94.4
EP %Bias -5.5 -3.9 -2.8 -7.4 -4.0 -4.4 -2.9 -2.7 -1.9 -9.9 -9.7 -7.9
Coverage 94.8 94.9 95.3 95.1 94.7 94.6 95.3 94.7 94.7 95.3 94.5 95.4
CS: compound symmetry covariance structure. AR(1): first-order autoregressive covariance structure. EP: equipredicability covariance structure. ρ¯:
mean pairwise correlation. True values of θ used for all the simulated scenarios are provided in Table A.1 in Appendix A.
2.5. Discussion
While there are many methods for analyzing crossover trials with continuous endpoints, there are
few studying crossover trials with time-to-event outcomes, which are often seen in practice. In this
paper, we have proposed a method using multiple imputation, assuming two candidate parametric
event time models, to impute censored post-treatment values. For each imputed dataset, ANCOVA,
with difference in period-specific baseline responses as a covariate, is applied to log-transformed
event times to estimate the log treatment-ratio of geometric means. Frequentist model averaging
with AIC weighting in conjunction with Rubin’s combination rule for multiple imputation is used for
overall estimation and inference. We showed that by utilizing baseline information, our method pro-
vided a more efficient or as efficient result than some other existing methods, including H-R test
and stratified Cox model, across different combinations of variance-covariance structures, percent-
age censoring and sample sizes. By using model averaging, we are able to provide a more flexible
method than assuming only one distribution in the imputation step, which can be subject to mis-
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Figure 2.1: Power comparison for the Hierarchical Rank test (H-R), stratified Cox model (SCB) and
proposed multiple imputation with model averaging and ANCOVA (MIMA) under a log-normal dis-
tribution and varying assumptions for the true variance structure (compound symmetry (CS), first-
order autoregressive (AR(1)), equipredictability (EP), mean pairwise correlation of baseline and
post-treatment values across the two periods (ρ¯ = 0.5, 0.7) and percentage censoring (10%,50%),
with 24 subjects per sequence. Stratified Cox model had non-convergence issues under CS struc-
ture with ρ¯ = 0.5 and 50% censoring, and under EP structure with ρ¯ = 0.5 and 50% censoring,
ρ¯ = 0.7 and 10% censoring and ρ¯ = 0.7 and 50% censoring, and hence power is not reported.
specification of the true underlying distribution. Furthermore, the H-R approach does not provide a
point estimator, while our regression-based method delivers an estimated ratio of geometric means
of event times for one treatment relative to the other with small or no bias and adequate 95% C.I.
coverage. The ratio of geometric means is a useful parameter in that it is equivalent to the ratio of
median event times under a log-normal distribution and other distributions that are symmetric on
the log-scale.
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Figure 2.2: Power comparison for the Hierarchical Rank test (H-R), stratified Cox model (SCB) and
proposed multiple imputation with model averaging and ANCOVA (MIMA) under an exponential dis-
tribution and varying assumptions for the true variance structure (compound symmetry (CS), first
order autoregressive (AR(1)), equipredictability (EP), mean pairwise correlation of baseline and
post-treatment values across the two periods (ρ¯ = 0.5, 0.7) and percentage censoring (10%,50%),
with 24 subjects per sequence. Stratified Cox model had non-convergence issues under EP struc-
ture with ρ¯ = 0.7 and 50% censoring, and hence power is not reported.
For our model-averaging approach, we only used two candidate models, log-normal and Weibull, to
impute censored post-treatment values. More distributions can readily be used. The candidate dis-
tributions should include those that cover a spectrum of anticipated plausible shapes of the survival
distribution for the outcome of interest. The relative success of our method, like other applications
of multiple imputation, is not expected to perform well if the imputation model is grossly misspec-
ified. We showed that using two candidate models provided efficient results with little bias for the
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Figure 2.3: Power comparison for the Hierarchical Rank test (H-R), stratified Cox model (SCB)
and proposed multiple imputation with model averaging and ANCOVA (MIMA) under a gamma
distribution and varying assumptions for the true variance structure (compound symmetry (CS),
first order autoregressive (AR(1)), equipredictability (EP), mean pairwise correlation of baseline and
post-treatment values across the two periods (ρ¯ = 0.5, 0.7) and percentage censoring (10%,50%),
with 24 subjects per sequence.
settings considered, and thus, more candidate models could potentially improve these results. Al-
though there is no upper limit on the number of models that can be fit, having an unnecessarily
large amount of models is also not recommended, as it may increase the overall computation time
without improving the power. It is also important to note that in order to properly use the model av-
erage approach to combine the parameter estimates, all of the candidate models need to estimate
the treatment effect with the same parameter.
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Table 2.3: Event times (minutes) for a 10-minute treadmill test in a 2×2 crossover clinical trial.
Placebo-drug sequence Drug-placebo sequence
Period 1 (placebo) Period 2 (drug) Period 1 (drug) Period 2 (placebo)
Subject X1 Y1 X2 Y2 Subject X1 Y1 X2 Y2
1 1.5 1 1 1.5 2 1 1 1 2.5
3 6 4 3.5 >10 4 6 >10 2.5 2.5
5 1 1 1.5 4.5 6 3 2 1 0.5
7 3.5 1.5 0.5 3 8 2.5 2.5 1.5 2
9 0.5 1 3.5 8 10 2 2.5 2.5 3
11 6 10 6 >10 12 1.5 4.5 2.5 1
13 0.5 0.5 1 >10 14 3.5 5.5 4.5 9.5
15 1 1 1 2.5 16 1 2 2 >10
17 1.5 1 0.5 0.5 18 6 >10 5 3.5
19 1 1.5 2 4 20 2 3 1.5 1.5
21 5 5.5 3 1.5 22 1.5 2.5 1.5 0.5
23 2.5 5 6 4.5 24 1.5 3.5 2.5 3
25 5 5.5 4.5 6 26 3.5 9 6 6
27 1 2 2.5 8.5 28 2 5.5 3.5 8
29 5 5.5 3.5 2 30 2.5 2.5 1 0.5
31 0.5 1 2 7.5 32 2.5 3.5 2.5 4
33 5 4 2 2 34 5.5 3 1 0.5
35 0.5 0.5 1 1.5 36 3 5.5 5 0.5
37 1.5 2 3 3 38 0.5 1 1 5.5
39 6 4 1.5 0.5 40 2.5 5 2.5 0.5
Median 1.5 1.75 2 3.5 Median 2.5 3.25 2.5 2.5
X1: baseline response in period 1. Y1: post-treatment response in period 1. X2: baseline response in period
2. Y2: post-treatment response in period 2.
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Figure 2.4: Kaplan-Meier curves for the time to a symptomatic cardiac-related event by treatment
group from a 2×2 crossover trial; (a) is for period 1 and (b) is for period 2.
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CHAPTER 3
HAZARD RATIO ESTIMATION IN SMALL SAMPLES
3.1. Introduction
In a typical survival analysis comparison of two groups, the hazard ratio, often called the relative
risk, is generally the focus of inference. If the hazard ratio can be assumed constant throughout
time, i.e., if the two groups have proportional hazard functions, it is conventional to use the Cox
proportional hazards model for estimation of relative risk and the log-rank test for hypothesis testing;
the latter can be derived as a score test via the Cox partial likelihood function (Cox, 1972). However,
Cox regression is a large sample method and small sample sizes (10-100 subjects per group) are
quite common in real data applications such as early phase clinical trials (Pocock, 1983). Besides
randomized clinical trials, observational studies involving a rare disease also often have limited
sample sizes. Therefore, it is important to study analysis methods for failure time data in small
samples. Johnson et al. (1982) performed a simulation study to investigate the Cox model with
one binary indicator as the covariate under small samples. They found that when total sample size
exceeds 40, there is no censoring, and there are equal number of subjects in the two groups, the
bias of the estimated log hazard ratio is reasonably low and the sample variance is similar to the
asymptotic variance. However, in smaller samples, there are non-trivial differences between the
actual and asymptotic formula-based variances.
To improve the estimation and inference of relative risk in studies with small sample sizes, Mehrotra
and Roth (2001) proposed a method based on a generalized log-rank (GLR) statistic for the 2-
group comparison. They showed that even though asymptotically the GLR method has similar
performance to the Cox approach, when the sample size is small, GLR is notably more efficient
than the Cox approach, in terms of mean squared error (MSE) for the log relative risk when there
are no ties.
In this chapter, we refine the GLR method by replacing previously formulated ‘approximate’ nui-
sance parameters with ‘exact’ counterparts, for settings with and without tied event times. We
show through numerical studies that the refined GLR (RGLR) statistic provides a notably smaller
bias than the GLR statistic and more commonly used methods such as the Cox and parametric
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models, while providing a high relative efficiency and maintaining coverage for 95% confidence
intervals. We provide further insights into the GLR statistic by developing an alternate estimation
approach for the nuisance parameters. We also compare the performance of the RGLR statistic
to parametric models, the Cox model, and the GLR approach. Furthermore, we examine RGLR’s
performance with respect to type I error and confidence interval coverage, and we compare RGLR
with correctly and incorrectly specified parametric models. Section 3.2 includes the derivation of
RGLR statistic for testing and estimation, where we also provide a different approach for estimating
the nuisance parameters. In Section 3.3, we study the numerical performance of the competing
methods through a simulation study. In Section 3.4, we apply the different methods to data from
two real data examples. Section 3.5 includes discussion and conclusions.
3.2. Methods
In this section we first develop the RGLR statistic under the assumption of no tied event times. We
then extend the method to handle tied event times.
3.2.1. Refined GLR Statistic for Hypothesis Testing with No Tied Event Times
Suppose there are two treatment groups A and B, and we randomize NA and NB subjects to
each of the groups, respectively. We assume for now that there are no tied observations. Let
t1 < t2 < · · · < tk denote the ordered observed event times for the combined data. Let T denote
the random variable for the event time, and SB(t) and hB(t) denote the survival and hazard function
for T in group B. By definition, we can write SB(t) = P (T > t) = exp(−
∫ t
0
hB(x)dx), so that
P (ti−1 < T ≤ ti|T > ti−1) = 1− P (T > ti|T > ti−1) = 1− exp(−pi), (3.1)
where pi =
∫ ti
ti−1
hB(x)dx. In the development of the original GLR statistic, 1 − exp(−pi) was
simplified to pi by invoking a first order Taylor series approximation (Mehrotra and Roth, 2001). In
this paper, motivated by a desire to reduce bias, we use the exact value of 1− exp(−pi) in a refined
GLR statistic (RGLR).
Let the random variables DiA, DiB denote the number of events in group A and B at ti, respectively,
and let Di = DiA + DiB . Let the random variables RiA, RiB denote the number of subjects still at
risk at time ti in group A and B, respectively. We then let riA and riB denote the observed number
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of subjects at risk at time ti in group A and group B, respectively, and the observed total number of
events and observed total number of subjects at risk at time ti as di and ri, respectively. Under the
no ties assumption, di = 1 ∀i. At ti, we can think of DiB as following a binomial distribution with
probability piiB = 1 − exp(−pi) and riB trials. Then, under the proportional hazards assumption, it
follows that the number of events in group A, DiA, will follow a binomial distribution with probability
piiA = 1− exp(−θpi) and riA number of trials, where θ is the hazard ratio for group A versus B. Let
Gi = {j : max(0, di− riB) ≤ j ≤ min(di, riA)}. Given di, riA, riB , pi, θ, the conditional distribution of
DiA follows a non-central hypergeometric distribution, and we can write the probability function as
λiA ≡ P (DiA = diA|RiA = riA, RiB = riB , Di = di, pi, θ) (3.2)
=
(
riA
diA
)(
riB
diB
)
(1− e−pi)diBe−pi(riB−diB)(1− e−θpi)diAe−θpi(riA−diA)∑
j∈Gi
(
riA
j
)(
riB
di−j
)
(1− e−pi)di−je−pi(riB−di+j)(1− e−θpi)je−θpi(riA−j) . (3.3)
Under the assumption of di = 1 ∀i, the conditional mean and variance ofDiA, denoted byEiA(riA, riB ,
θ, pi) and ViA(riA, riB , θ, pi), can be derived as the following expressions:
EiA(riA, riB , θ, pi) =
∑
Gi
diAλiA =
riA(e
θpi − 1)
riA(eθpi − 1) + riB(epi − 1) (3.4)
ViA(riA, riB , θ, pi) =
∑
Gi
d2iAλiA −
(∑
Gi
diAλiA
)2
=
riA(e
θpi − 1)riB(epi − 1)
[riA(eθpi − 1) + riB(epi − 1)]2 . (3.5)
Note that the vector of nuisance parameters p = (p1, p2, . . . , pk) is unknown and needs to be
estimated. We use an unconditional approach, as suggested by Mehrotra and Roth (2001). The
estimate of nuisance parameter pi is found by maximizing the product of two unconditional binomial
likelihoods, Bin(riA, 1− exp(−θpi)) and Bin(riB , 1− exp(−pi)):
L(pi|θ) = pidiAiA (1− piiA)riA−diApidiBiB (1− piiB)riB−diB (3.6)
= (1− e−θpi)diA(e−θpi)riA−diA(1− e−pi)diB (e−pi)riB−diB . (3.7)
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Because we are assuming no ties, the solution can be simplified to
p˜i,θ =

log
(
θriA+riB
θriA+riB−1
)
, when diA = 0, diB = 1
1
θ log
(
θriA+riB
θriA+riB−θ
)
, when diA = 1, diB = 0.
(3.8)
Let p˜(θ) denote the estimated nuisance parameter vector p, where p˜(θ) = (p˜1,θ, p˜2,θ, . . . , p˜k,θ).
Then, the RGLR test statistic for the general null hypothesis H0 : θ = θ0 is
RGLR[θ0, p˜(θ0)] =
∑k
i=1[diA − EiA(riA, riB , θ0, p˜i,θ0)]2∑k
i=1 ViA(riA, riB , θ0, p˜i,θ0)
. (3.9)
The reference distribution for the RGLR statistic is approximated with an F-distribution with degrees
of freedom 1 and k∗, where k∗ =
∑
i min(di, ri − di, riA, riB). This is the same distribution as that
used for the original GLR statistic (Mehrotra and Roth, 2001). We conjecture that our RGLR statistic
has the same reference distribution as the GLR statistic because we only changed the approximate
nuisance parameters in the original GLR formulation with ‘exact’ counterparts, which presumably
should not affect the distribution. This is analogous to using different estimators of variance com-
ponents (nuisance parameters) but the same reference null distributions in common linear mixed
effects analyses. This conjecture is strongly supported via simulations in Section 3.3. Note that
under the most commonly used null hypothesis θ0 = 1, estimation of the nuisance parameters is no
longer required, and the RGLR statistic reduces to the usual log-rank test statistic (Mantel, 1966),
which has an asymptotic distribution of χ21.
Of note, it is easy to see that the equivalence between the RGLR statistic and Cox score statistic
as sample size goes to infinity. As sample size increases, the estimate of pi is approximately zero
for most i’s, because the time interval becomes smaller between two consecutive events and the
probability of having an event in the interval approaches zero. It can be shown through L’Hopital’s
rule that when pi → 0, the RGLR statistic reduces to the score statistic from the Cox model.
This demonstrates that the RGLR statistic is asymptotically similar to the Cox score statistic; this
theoretical expectation is supported using simulations in Section 3.3.
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3.2.2. Estimation of Nuisance Parameters
The development above is similar to the logic provided by Mehrotra and Roth (2001). However,
to provide additional insight, we show that in the set up of Mehrotra and Roth’s GLR statistic,
the estimated nuisance parameter p˜i,θ can also be estimated using the inverse-variance weighted
average of the corresponding estimates of the failure probability in each group. Recall that we think
of the number of events at time ti in group A and B as following two binomial distributions with
probability piiA and piiB , respectively. In the setting of GLR, piiB = pi and piiA = θpi using the Taylor
approximation. Therefore, there are two natural estimates of the failure probability, pˆiiB = diB/riB
from group B and pˆiiA = diA/riA from group A. Thus, we have two estimates of the nuisance
parameter, namely pˆiB,θ = diB/riB and pˆiA,θ = diA/(θriA). Hence,
Var(piA|RiA = riA) = Var(DiA)
θ2r2iA
=
pi(1− θpi)
θriA
and
Var(piB |RiB = riB) = Var(DiB)
r2iB
=
pi(1− pi)
riB
.
Accordingly, if we equate pi with the inverse-variance weighted average of pˆiA,θ and pˆiB,θ, i.e., set
pi =
pˆiA,θ
V ar(piA|RiA=riA) +
pˆiB,θ
V ar(piB |RiB=riB)
1
V ar(piA|RiA=riA) +
1
V ar(piB |RiB=riB)
,
and solve for pi, we get the same estimated p˜i,θ as that obtained via maximization of the product
of the aforementioned two Binomial distributions (direct MLE approach). Since the formula for p˜i,θ
is somewhat complex, using the inverse-variance weighted average approach provides an intuitive
and simple path to estimate the nuisance parameters.
In the setting of RGLR, however, these two approaches do not give the same estimates, because
the relationship between the nuisance parameter pi and failure probability piiB is no longer linear.
There are no simple closed-form solutions for the nuisance parameters using the inverse-variance
weighted average approach. Although numerical solutions can still be achieved, we prefer the direct
MLE approach because it delivers an exact closed-form solution. Further details of the derivation
using the two approaches for the RGLR statistic can be found in Appendix B.
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3.2.3. Inference using the Refined GLR Estimator for Relative Risk
The RGLR statistic is in quadratic form, which guarantees a unique minimum. Because small
values of the RGLR statistic support the null hypothesis, we can derive an estimator for relative
risk, θˆRGLR, by finding the θ that minimizes the RGLR test statistic.
The confidence interval of the RGLR estimator can then be calculated using the F(1, k∗) as the
reference distribution. Therefore, the 100(1−α)% confidence interval for θˆRGLR is (θLRGLR, θURGLR),
where
θLRGLR = inf
θ
{θ : RGLR(θ, p˜(θ)) ≤ Fα(1, k∗)} (3.10)
θURGLR = sup
θ
{θ : RGLR(θ, p˜(θ)) ≤ Fα(1, k∗)}. (3.11)
3.2.4. Extension of RGLR to Accommodate Tied Event Times
In this section, we extend the RGLR statistic to allow for tied event times so that the method is
more applicable for real data sets. There are several approaches for handling ties in the Cox
model, including Breslow (1974), Efron (1977) and Kalbfleisch and Prentice (1973). Mehrotra and
Roth (2011) extended the GLR statistic to incorporate ties following analogs of Kalbfleisch and
Prentice’s and Efron’s approaches. We propose to use Efron’s approach to handle ties for RGLR
statistic, given that Efron’s method is easier to implement.
With ties, the previous assumption that di = 1 ∀i no longer holds, and the conditional expected
value and variance functions need to be updated to average over all possible orderings of tied
event times at each time point i. Suppose in the time interval (ti−1, ti], there are di(> 1) event
times given by ti,1 < ti,2 < · · · < ti,di . Now, if we construct an average 2 × 2 life table at the
unobserved true event time ti,j , the average number of failure event times for group A and B is
diA/di and diB/di, respectively, and the average number of subjects still at risk is riA− jdiA/di and
riB − jdiB/di for group A and B, respectively, where j = 1, 2, . . . , di. Then, summing across the di
time points, we get
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E¯iA(θ, pi,j) =
di∑
j=1
EiA
(
riA − (j − 1)diA
di
, riB − (j − 1)diB
di
, θ, pi,j
)
(3.12)
V¯iA(θ, pi,j) =
di∑
j=1
ViA
(
riA − (j − 1)diA
di
, riB − (j − 1)diB
di
, θ, pi,j
)
, (3.13)
where EiA and ViA are shown in equation (3.4) and (3.5), using the margins of the average 2 × 2
life table at each of the unobserved true event times for the di events.
We derive the estimated nuisance parameter using the likelihood approach as before, where now
L(pi,j |θ) = pidiA/diiA (1− piiA)riA−jdiA/dipidiB/diiB (1− piiB)riB−jdiB/di (3.14)
= (1− e−θpi,j )diA/di(e−θpi,j )riA−jdiA/di(1− e−pi,j )diB/di(e−pi,j )riB−jdiB/di . (3.15)
To find the nuisance parameter that maximizes equation (3.14), we take the log and the first-order
derivative respect to pi,j and set it to zero. The estimating equation is:
diA
di
· θe
−θpi,j
1− e−θpi,j − θ
(
riA − j diA
di
)
+
diB
di(1− e−pi,j ) −
(
riB − j diB
di
)
= 0 (3.16)
The estimating equation (3.16) is a nonlinear function of pi,j , and there is no closed-form solution.
Therefore, we use a numerical approach to solve for pi,j at ti,j ; let p˜(θ) denote the estimated
nuisance parameter matrix, where entry (i, j) is denoted as p˜i,j,θ. Therefore, using Efron’s approach
to extend RGLR for tied event times, the RGLRE test statistic for the null hypothesis H0 : θ = θ0 is
RGLRE [θ0, p˜(θ0)] =
∑k
i=1[diA − E¯iA(θ0, p˜i,j,θ0)]2∑k
i=1 V¯iA(θ0, p˜i,j,θ0)
. (3.17)
The reference distribution used for RGLRE is an F-distribution with degrees of freedom 1 and k∗,
where k∗ =
∑
i min(di, ri−di, riA, riB). This is the same distribution as that used for RGLR with no
ties. Again, this approximation is based on a conjecture that is supported by simulations, as shown
later. Of note, RGLRE and RGLR are identical when there is no tied event times.
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3.3. Simulation Study
We first compared the performance of the RGLR statistic to the Cox proportional hazards and
parametric models, and to the GLR approach when there are no tied observations. We carried out
a simulation study to examine issues of bias, efficiency, type I error and the nominal 95% confidence
interval coverage. For estimation with the parametric model, we examined estimation under the true
versus a misspecified distribution for the simulated survival times.
For each of the NA and NB subjects in group A and B, independent entry time eij was generated
from a uniform distribution on (0, T), where i indicates subject and j = 1, 0 indicates group A or
B, respectively. Independent of the entry time, survival time siA was generated from Weibull (rate=
0.5θ, shape=2), and siB was generated from Weibull (rate=0.5, shape=2), so that the hazard ratio
was θ. Note that the probability density function of a Weibull distribution with shape parameter
α and rate parameter λ is f(t) = αλtα−1 exp(−λtα). The trial time for each subject was hence
tij = min(sij , T − eij).
We varied the sample size, percentage of censoring and the hazard ratio between the two groups
to compare the performance of the different methods. Sample size per group was varied as NA =
NB = 10, 20, 40, 100. We considered percentage of censoring for the total sample of 0% and 50%.
The percentage of censoring was controlled by changing the final analysis time T. For example, for
20 subjects per group with true log hazard ratio of 0.6, with T=2 the mean censoring was 50.7%
and the average number of events was 20.3. The log hazard ratio, denoted by ln(θ), took values of
0, 0.6 and 1.2. Simulation results are based on 5000 replications.
Given the small sample sizes, a problem referred to as ‘monotone likelihood’ was encountered in
some simulated datasets, where the highest event time in one group precedes the smallest event
time in the other group (Bryson and Johnson, 1981). Under this scenario, the hazard ratio estimate
from the Cox model is infinite and not reliable. Therefore, we deleted any simulated dataset in
which this occurred, and if for a set of parameters of interest, there were more than 1% simulated
datasets with a monotone likelihood, the results were not reported. For this reason results for 10
subjects per group are not considered for scenarios with 50% censoring.
For each simulation scenario, we compare the empirical bias, relative efficiency and the empiri-
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cal coverage probability for the 95% confidence interval for all scenarios considered for the para-
metric (Weibull) regression model, Cox model, GLR and RGLR. The estimated log hazard ratio
from fitting the Weibull regression is estimated by dividing the negative of the coefficient for the
covariate Z, the group indicator, by the estimated scale parameter. The estimated log hazard
ratio from the Cox model is the estimated coefficient for Z. Bias was reported for the case of
ln(θ) = 0 and percentage bias, defined as 100 times the ratio of bias to the true value, was re-
ported for ln(θ) = 0.6 and 1.2. The relative efficiency was calculated as the ratio of the MSE
of the Cox model estimator and the estimator of the given competing method, i.e., %RMSE =
100×MSE of Cox/MSE of competing method. Accordingly, %RMSE>100% indicates that the tar-
get method is more efficient than the Cox model.
3.3.1. Results on Estimation without Tied Event Times
For the results shown in Table 3.1, the RGLR statistic always has the smallest bias among the
four methods and provides higher efficiency relative to the Cox model, even with 100 subjects per
group. Compared to the parametric model, RGLR still has a higher relative efficiency in small
samples (fewer than 20 subjects per group under 0% censoring and fewer than 40 subjects per
group under 50% censoring). While GLR has the highest relative efficiency under small samples,
it has a bigger bias than RGLR, and fails to maintain the nominal 95% coverage rate in some
scenarios, which will be further discussed in Section 3.3.2. It should also be noted that the results
of the parametric method are based on the true distribution. For real data examples, it is quite
difficult to make a correct assumption about the true distribution when sample size is small. When
a wrong distribution is assumed, we would expect the parametric method to perform worse. Thus,
the parametric method carries the risk of making the wrong assumption for the true distribution,
whereas the RGLR method does not require any knowledge about the underlying distribution. We
will examine the impact of misspecification of the survival distribution later in Section 3.3.3.
3.3.2. Results on Hypothesis Testing without Tied Event Times
Table 3.1 also reports the empirical coverage probability for the 95% confidence interval (C.I.).
Note that under the null hypothesis of H0 : ln(θ) = 0, i.e., the hazard ratio is 1, and a two-tailed 5%
significance level, 100 minus the coverage probability is equal to the type I error rate. Therefore, a
coverage probability below 95% under the null indicates an inflated type I error. In Table 3.1, a value
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Table 3.1: Empirical bias, percent ratio of MSE relative to Cox model and coverage probability for 95% C.I. for ln(θ) =
0, 0.6, 1.2 based on 5000 simulations and an underlying Weibull distribution for the survival times.
ln(θ) = 0 ln(θ) = 0.6 ln(θ) = 1.2
Censoring N Method Bias %RMSE Cov %Bias %RMSE Cov %Bias %RMSE Cov
0% 10 Cox (Wald) -0.000 100 94.2 8.42 100 94.7 8.30 100 96.5
Cox (Score) -0.000 100 [93.3] 8.42 100 [93.5] 8.30 100 94.4
Weibull -0.001 102 [92.7] 11.3 104 [93.1] 11.1 114 [93.5]
GLR -0.000 135 95.1 -6.50 134 94.8 -7.04 143 [93.3]
RGLR -0.000 114 95.1 1.52 114 95.2 1.49 117 95.7
20 Cox (Wald) 0.001 100 94.6 4.36 100 94.6 3.99 100 95.0
Cox (Score) 0.001 100 [94.2] 4.36 100 [94.0] 3.99 100 94.4
Weibull 0.001 101 [93.4] 5.63 104 [93.7] 5.54 111 [93.9]
GLR 0.001 119 94.9 -3.69 115 [94.0] -3.46 116 [93.1]
RGLR 0.001 108 94.9 0.53 108 94.7 0.42 108 94.7
40 Cox (Wald) -0.005 100 94.8 1.01 100 94.6 1.38 100 95.0
Cox (Score) -0.005 100 94.6 1.01 100 94.8 1.38 100 94.7
Weibull -0.005 101 94.5 1.76 104 94.7 2.19 109 94.5
GLR -0.005 111 95.1 -3.42 107 [94.3] -2.45 106 [94.0]
RGLR -0.005 105 95.1 -1.12 104 94.8 -0.49 104 94.7
100 Cox (Wald) -0.001 100 95.1 0.75 100 94.6 0.75 100 95.0
Cox (Score) -0.001 100 95.0 0.75 100 94.6 0.75 100 94.9
Weibull -0.001 101 94.9 0.96 102 94.6 1.03 108 94.8
GLR -0.001 105 95.2 -1.23 103 94.5 -0.86 102 94.7
RGLR -0.001 102 95.2 -0.21 101 94.6 -0.05 102 95.0
50% 20 Cox (Wald) -0.001 100 95.4 4.91 100 95.3 5.51 100 96.2
Cox (Score) -0.001 100 94.4 4.91 100 [94.3] 5.51 100 94.9
Weibull -0.000 99 [94.0] 7.24 104 [94.1] 7.40 108 94.5
GLR -0.001 123 96.1 -5.67 125 95.5 -5.51 128 94.6
RGLR -0.001 110 96.1 0.13 110 95.7 0.66 112 95.9
40 Cox (Wald) -0.005 100 95.5 1.45 100 95.5 1.95 100 95.2
Cox (Score) -0.005 100 95.0 1.45 100 95.2 1.95 100 94.9
Weibull -0.004 100 95.1 2.94 101 95.1 3.23 105 94.7
GLR -0.004 112 95.6 -4.21 112 95.6 -3.78 112 94.7
RGLR -0.004 105 95.6 -1.18 105 95.8 -0.69 106 95.3
100 Cox (Wald) 0.001 100 95.3 0.57 100 94.9 0.81 100 95.2
Cox (Score) 0.001 100 95.2 0.57 100 94.8 0.81 100 95.1
Weibull 0.001 100 95.0 1.10 101 94.7 1.35 104 94.8
GLR 0.001 105 95.5 -1.94 105 95.0 -1.66 104 94.6
RGLR 0.001 102 95.5 -0.62 102 95.1 -0.37 103 95.1
Bias is reported for ln(θ) = 0, and percentage bias is reported for ln(θ) = 0.6 and 1.2. %RMSE = 100 ×
MSE of Cox/MSE of competing method. Results for 10 per group with 50% censoring are not reported due to monotone likelihood
problems in more than 1% of the simulated datasets. Coverage probability more than Z0.975 standard errors below 95% is in square
brackets. N : sample size per group. Cov: coverage probability for 95% C.I. Cox (Wald): Cox proportional hazards model with Wald
test. Cox (Score): Cox proportional hazards model with Score test. Weibull: Weibull regression. GLR: Generalized log-rank approach.
RGLR: Refined GLR approach.
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in square brackets indicates that the coverage probability is more than Z0.975 standard errors less
than the nominal rate of 95%, which implies that the type I error rate is more than Z0.975 standard
errors above the nominal rate of 5%. We performed a Wald test for the estimated θ using parametric
(Weibull) regression and both Wald and Score tests using Cox model. When sample size was 10
and 20 per group, the Wald test from Weibull regression and Cox Score and Cox Wald tests tended
to provide an inflated type I error rate, while our RGLR statistic controlled the type I error rate under
5%. For ln(θ) = 0.6 and 1.2, RGLR consistently maintained at least 95% coverage rate across all
simulated scenarios. On the other hand, GLR, Cox and parametric model failed to maintain the
95% coverage rate when sample size was small.
3.3.3. Misspecification of the Failure Time Distribution (No Tied Event Times)
As mentioned earlier, it is not always possible to assume the correct distribution when using a given
parametric approach in a real data situation. When a wrong parametric model is fit to the data, we
would expect the resulting estimator to be biased. On the other hand, the RGLR approach does not
make any assumption about the underlying survival distribution. We carried out a simulation study
on the effect of misspecification, where the data were generated from a Gompertz distribution. The
survival time in group A was generated from a Gompertz(shape=0.5, rate=0.2θ), and the survival
time in group B was generated from a Gompertz(shape=0.5, rate=0.2), so that proportional hazards
still holds with hazard ratio θ. Each subject also had an independent entry time, and the trial was
administratively censored by a fixed time T .
We again considered three different values for the log hazard ratio: ln(θ) = 0, 0.6, 1.2, percentage
censoring of 0% and 50%, and varied the number of subjects per group as 10, 20, 40, 100. For
each simulation, we fit the exponential, Weibull and Cox models, and applied the GLR and RGLR
methods. Figure B.1 in the Appendix B shows the different hazard functions from Gompertz, Weibull
and exponential distributions.
When Gompertz was the true distribution, fitting exponential and Weibull regression under 0% cen-
soring resulted in large bias and low percent RMSE when ln(θ) > 0, as shown in the Table 3.2. The
percentage bias from fitting exponential regression was as large as 40%, and its percent RMSE
ranged from 14% to 210%. However, with a percentage bias around 30-40%, the high percent
RMSE is largely meaningless. On the other hand, when the log hazard ratio was 0, exponential
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regression had a very small absolute bias and a high percent RMSE. However, given its poor per-
formance in the case of non-zero log hazard ratio, this behavior indicates a tendency towards atten-
uation bias. Li, Klein, and Moeschberger (1996) examined the behavior of exponential regression
under misspecification in the context of hypothesis testing, and found that exponential regression
notably underestimates the nominal 5% alpha level when the true distribution is Gompertz and
substantially overestimates when the hazard rate is decreasing. This is consistent with our finding
that the exponential model performed poorly for non-zero log hazard ratio scenarios. Weibull re-
gression, although more stable than exponential regression, still resulted in a bias of 10% or more
when the sample size was at least 20 subjects per group under 0% censoring. It also started to
lose efficiency as sample size increased, for example, with %RMSE=63% when ln(θ) = 1.2 under
0% censoring.
Compared to the parametric approach, the Cox model, GLR and RGLR approaches are not subject
to misspecification of the underlying distribution and thus provided much more stable results. The
bias of RGLR approach was the smallest across all the simulated scenarios, and it also delivered
a higher relative efficiency than the Cox model and Gompertz model when there were fewer than
100 subjects per group. The efficiency of the Gompertz model relative to the Cox model increased
above 100% when the sample size reached 100 per group, which is expected.
When percentage censoring increased to 50%, all methods performed better than with 0% censor-
ing. This could be due to the fact that some extreme values were censored under 50% censoring.
However, exponential and Weibull regression were still the least ideal approaches. RGLR, on the
other hand, consistently showed the lowest bias and high relative efficiency, relative to Cox and
Gompertz model.
As shown in Table 3.2 and mentioned earlier, the exponential model underestimated Type I error
and had poor coverage. The Cox model, especially using the score test, and GLR tended to provide
a slightly lower coverage than desired. On the other hand, the RGLR approach is more stable and
was able to maintain at least 95% coverage.
Figure 3.1 panels (a)-(c) show the empirical densities of the estimators from the different meth-
ods with an underlying Gompertz distribution and 0% censoring and 20 subjects per group for
ln(θ) = 0, 0.6, and 1.2, respectively. The vertical line is drawn at the true hazard ratio. As noted
35
in the simulation results, in all three cases, the exponential model was adversely impacted by mis-
specification of the underlying true distribution. The RGLR estimates centered more closely around
the true value than those from the Cox model.
Table 3.2: Empirical bias, percent ratio of MSE relative to Cox model and coverage probability for 95% C.I. for ln(θ) =
0, 0.6, 1.2 based on 5000 simulations and an underlying Gompertz distribution for the survival times.
ln(θ) = 0 ln(θ) = 0.6 ln(θ) = 1.2
Censoring N Method Bias %RMSE Cov %Bias %RMSE Cov %Bias %RMSE Cov
0% 10 Cox (Wald) -0.000 100 [94.3] 8.98 100 95.1 7.96 100 96.8
Cox (Score) -0.000 100 [93.4] 8.98 100 [94.2] 7.96 100 94.5
Gompertz 0.005 94 [92.3] 15.5 94 [93.0] 14.1 99 [93.7]
Exp -0.002 350 99.7 -39.8 210 98.5 -35.8 139 [93.4]
Weibull 0.001 140 95.5 -5.10 138 95.2 -3.95 144 94.7
GLR 0.000 135 95.2 -6.14 135 95.0 -7.36 143 [93.5]
RGLR 0.000 114 95.2 2.04 115 95.7 1.17 117 96.0
20 Cox (Wald) 0.003 100 94.5 4.06 100 95.0 3.68 100 95.1
Cox (Score) 0.003 100 [94.0] 4.06 100 94.7 3.68 100 94.7
Gompertz 0.005 97 [93.7] 7.36 98 [94.1] 6.90 102 94.6
Exp 0.003 324 99.8 -39.6 132 96.9 -35.7 71 [81.2]
Weibull 0.003 142 96.8 -10.3 133 95.7 -9.02 132 [94.0]
GLR 0.003 119 94.9 -4.02 116 94.5 -3.55 116 [93.4]
RGLR 0.003 108 94.9 0.21 107 95.1 0.37 108 94.9
100 Cox (Wald) 0.002 100 94.9 0.94 100 94.9 0.81 100 95.1
Cox (Score) 0.002 100 94.8 0.94 100 94.8 0.81 100 95.0
Gompertz 0.002 100 94.8 1.51 100 94.7 1.41 102 94.7
Exp 0.001 294 99.9 -40.3 34 [65.9] -36.3 14 [5.4]
Weibull 0.002 140 97.5 -14.2 95 [93.6] -12.8 63 [83.6]
GLR 0.002 105 94.9 -1.04 103 94.5 -0.80 103 94.7
RGLR 0.002 102 94.9 -0.02 102 94.8 0.01 102 94.9
50% 20 Cox (Wald) 0.005 100 95.6 4.91 100 95.5 4.81 100 95.8
Cox (Score) 0.005 100 94.8 4.91 100 94.7 4.81 100 94.9
Gompertz 0.007 97 94.5 7.99 98 94.8 7.55 96 94.9
Exp 0.006 142 97.9 -7.24 134 96.9 -7.71 138 95.8
Weibull 0.006 112 95.7 2.93 112 95.7 1.95 119 95.5
GLR 0.004 121 96.2 -4.35 122 95.6 -4.80 124 95.1
RGLR 0.005 109 96.2 0.69 109 95.6 0.53 111 95.8
40 Cox (Wald) -0.010 100 95.0 0.45 100 95.2 1.14 100 95.5
Cox (Score) -0.010 100 94.6 0.45 100 94.8 1.14 100 95.0
Gompertz -0.010 99 94.5 2.22 99 94.8 2.64 97 94.6
Exp -0.008 138 97.3 -10.9 124 96.3 -10.4 116 [94.2]
Weibull -0.009 111 95.7 -2.28 109 95.5 -2.26 114 95.7
GLR -0.009 111 95.2 -4.41 111 95.4 -3.91 112 94.6
RGLR -0.010 105 95.2 -1.83 105 95.5 -1.18 105 95.3
100 Cox (Wald) 0.000 100 95.1 0.62 100 95.0 0.69 100 94.8
Cox (Score) 0.000 100 94.9 0.62 100 94.7 0.69 100 94.7
Gompertz 0.000 100 94.7 1.26 99 94.7 1.40 99 94.6
Exp 0.001 136 97.5 -11.1 112 95.4 -10.7 90 [91.4]
Weibull 0.000 111 95.5 -3.11 108 95.1 -3.25 109 94.8
GLR 0.000 105 95.1 -1.48 104 94.9 -1.47 104 94.4
RGLR 0.000 102 95.1 -0.39 102 95.0 -0.34 102 94.9
Bias is reported for ln(θ) = 0, and percentage bias is reported for ln(θ) = 0.6 and 1.2. %RMSE = 100 ×
MSE of Cox/MSE of competing method. Results for 10 per group with 50% censoring are not reported due to monotone likelihood
problems in more than 1% of the simulated datasets. Coverage probability more than Z0.975 standard errors below 95% is in square
brackets. N : sample size per group. Cov: coverage probability for 95% C.I. Cox (Wald): Cox proportional hazards model with Wald
test. Cox (Score): Cox proportional hazards model with Score test. Weibull: Weibull regression. GLR: Generalized log-rank approach.
RGLR: Refined GLR approach.
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Figure 3.1: Empirical densities of estimators from the Gompertz, exponential, and Weibull para-
metric survival models, Cox model, generalized log-rank (GLR) and refined GLR (RGLR) (5000
simulations for 20 subjects per group with 0% censoring and an underlying Gompertz distribution)
with a true hazard ratio of (a) 1 (b) 1.82 (c) 3.32. A vertical line is drawn at the true hazard ratio.
3.3.4. Simulation Results with Tied Event Times
To compare the performance of RGLRE to competing methods when ties in the event times are
present, we again generated the data from a Weibull distribution. The set up was the same as the
scenario with no tied observations, where survival time in group A was from Weibull (rate=0.5θ,
shape=2), and survival time in group B was from Weibull (rate=0.5, shape=2). Ties were created
by rounding the event times to one digit after the decimal place, which is equivalent to rounding
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to the nearest month if the trial time unit is in years. There were approximately 15-20% tied event
times, calculated as the percentage of non-unique event times in group A and B, in the the simu-
lation studies. We compared the proposed RGLR extension for ties, RGLRE , Weibull regression,
Cox model and GLR extension for ties, the latter two using Efron’s approximation. The pattern of
simulation results are very similar to that under no ties, and results are reported in Table 3.3.
When ties are present, with small sample sizes, RGLRE still delivered the smallest bias among all
the methods considered, and provided higher efficiency than both Cox model that adjusts for ties
using Efron’s approximation and Weibull regression. It also controlled type I error and maintained
at least 95% coverage rate, while both Cox model and Weibull tended to have inflated type I error
under small samples; of note, GLRE failed to deliver adequate 95% confidence interval coverage
in some cases.
3.4. Application to Two Real Datasets
We apply the RGLR and other competing methods to data from two clinical trials involving lung
cancer (Kalbfleisch and Prentice, 1980) and bladder cancer (Pagano and Gauvreau, 2000).
3.4.1. Lung Cancer Clinical Trial
Kalbfleisch and Prentice (1980) reported results for a lung cancer trial with 137 male patients.
There were 69 patients randomized patients to a standard chemotherapy and 68 patients to a test
chemotherapy. Patients were categorized into four histological tumor types: squamous, small cell,
adenoma and large cell. The outcome variable was time to death (in days). Kaplan-Meier curves
comparing patients on standard and test chemotherapy with different cell types are presented in
Figure 3.2.
There were no tied event times in the large cell group, so we applied Weibull regression, Cox model,
GLR and RGLR. The remaining groups all had some tied event times; therefore, we applied Weibull
regression, Cox model with Efron’s approximation for ties, GLRE , RGLRE . For patients with large
cell group, GLR and RGLR provided a smaller estimated hazard ratio (test/standard) and narrower
95% C.I. than Weibull and Cox model, as shown in Figure 3.3 (b). The estimated hazard ratio (95%
C.I.) was 1.64 (0.76, 3.55) using Weibull regression, 1.54 (0.69, 3.41) using Cox regression, 1.44
(0.71, 2.96) using GLR and 1.49 (0.69, 3.22) using RGLR. For patients with squamous, adenoma
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Table 3.3: Empirical bias, percent ratio of MSE relative to Cox model and coverage probability for 95% C.I. for ln(θ) =
0, 0.6, 1.2 based on 5000 simulations and an underlying Weibull distribution for the survival times with tied observations.
ln(θ) = 0 ln(θ) = 0.6 ln(θ) = 1.2
Censoring N Method Bias %RMSE Cov %Bias %RMSE Cov %Bias %RMSE Cov
0% 10 CoxE (Wald) -0.001 100 94.7 7.30 100 94.6 6.36 100 96.6
CoxE (Score) -0.001 100 [93.7] 7.30 100 [93.8] 6.36 100 94.7
Weibull -0.001 99 [92.7] 11.5 101 [93.0] 11.3 107 [93.3]
GLRE -0.000 138 95.3 -8.46 136 94.6 -9.50 140 [92.6]
RGLRE -0.000 116 95.3 -0.09 116 95.0 -0.70 117 95.7
20 CoxE (Wald) 0.001 100 94.6 3.52 100 94.6 2.91 100 94.8
CoxE (Score) 0.001 100 [94.1] 3.52 100 [94.3] 2.91 100 94.4
Weibull 0.002 99 [93.4] 5.69 102 [93.7] 5.62 106 [93.8]
GLRE 0.001 120 94.9 -4.95 115 [94.0] -4.74 114 [92.7]
RGLRE 0.001 109 95.0 -0.55 108 94.7 -0.75 108 94.7
100 CoxE (Wald) -0.001 100 95.0 0.52 100 94.7 0.65 100 95.0
CoxE (Score) -0.001 100 95.0 0.52 100 94.6 0.65 100 95.0
Weibull -0.001 101 94.9 0.96 102 94.6 1.05 108 94.8
GLRE -0.001 106 95.2 -1.21 102 94.5 -1.78 102 94.7
RGLRE -0.001 103 95.1 -0.23 101 94.7 -0.35 102 95.0
50% 20 CoxE (Wald) -0.001 100 95.4 3.91 100 95.4 4.19 100 96.3
CoxE (Score) -0.001 100 94.5 3.91 100 94.6 4.19 100 95.1
Weibull -0.000 96 [94.0] 7.45 100 [93.8] 7.67 101 94.5
GLRE -0.001 123 96.0 -6.61 124 95.5 -6.72 126 94.6
RGLRE -0.001 110 96.0 -0.89 110 95.8 -0.67 113 96.0
40 CoxE (Wald) -0.004 100 95.6 0.90 100 95.7 1.06 100 95.2
CoxE (Score) -0.004 100 95.2 0.90 100 95.2 1.06 100 94.8
Weibull -0.004 99 94.9 3.22 99 94.7 3.41 101 94.5
GLRE -0.004 112 96.0 -4.70 111 95.6 -4.55 111 94.5
RGLRE -0.004 106 96.0 -1.73 105 95.8 -1.52 106 95.2
100 CoxE (Wald) 0.001 100 95.3 0.79 100 95.5 0.63 100 95.2
CoxE (Score) 0.001 100 95.1 0.79 100 95.2 0.63 100 95.1
Weibull 0.001 100 95.0 1.93 101 95.2 1.93 101 95.2
GLRE 0.001 105 95.4 -1.64 105 95.5 -1.76 104 95.4
RGLRE 0.001 102 95.4 -0.38 102 95.6 -0.52 102 95.5
Bias is reported for ln(θ) = 0, and percentage bias is reported for ln(θ) = 0.6 and 1.2. %RMSE = 100 ×
MSE of Cox/MSE of competing method. Results for 10 per group with 50% censoring are not reported due to monotone likelihood
problems in more than 1% of the simulated datasets. Coverage probability more than Z0.975 standard errors below 95% is in square
brackets. N : sample size per group. Cov: coverage probability for 95% C.I. CoxE (Wald): Cox proportional hazards model using Efron’s
method for ties with Wald test. CoxE (Score): Cox proportional hazards model using Efron’s method for ties with Score test. Weibull:
Weibull regression. GLRE : Generalized log-rank approach using Efron’s method for ties. RGLRE : Refined GLR approach using Efron’s
method for ties.
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and small cell types, four methods, Weibull, Cox model with Efron’s approximation, GLRE and
RGLRE provided similar results, as shown in Figure 3.3 panels (a), (c) and (d). The true hazard
ratio is unknown in a real data example, but based on our simulation results, the RGLR approach
has the smallest bias and maintains coverage for 95% C.I. in small samples, and thus, is expected
to be closer to the truth.
Figure 3.2: Lung cancer data example: Kaplan-Meier curves for time to death comparing test to
standard chemotherapy by cell types.
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(a) squamous cell (b) large cell (c) adenoma cell and (d) small cell. Data from Kalbfleisch and Prentice (1980).
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Figure 3.3: Lung cancer data example: Estimated hazard ratio and 95% confidence interval com-
paring test to standard chemotherapy by cell types.
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(a) squamous cell (b) large cell (c) adenoma cell and (d) small cell. Cox: Cox regression. Weibull: Weibull
regression. GLR: Generalized log-rank approach. RGLR: Refined GLR approach. CoxE : Cox regression using
Efron’s method to adjust for tied events. Weibull: Weibull regression. GLRE : Generalized log-rank approach
using Efron’s method to adjust for tied events. RGLRE : Refined GLR approach using Efron’s method to adjust
for tied events. Data from Kalbfleisch and Prentice (1980).
3.4.2. Bladder Cancer Clinical Trial
Pagano and Gauvreau (2000) reported results on a bladder cancer clinical trial. The study included
86 patients in total, who were assigned to either placebo or chemotherapy (Thiotepa) after surgery.
The outcome of interest was time to recurrence (in months). We further divided the subjects into
two groups according to the number of tumors removed at surgery, one or multiple, and assessed
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the treatment effect. Among patients with one tumor removed, 26 patients were on placebo and 23
were on chemotherapy. Among those with multiple tumors removed, 22 patients were on placebo
and 15 were on chemotherapy. Figure 3.4 panels (a) and (b) present the Kaplan-Meier curves
comparing patients on placebo and chemotherapy with one or multiple tumors removed.
Because of the tied event times in the data set, we again applied Weibull regression, Cox model with
Efron’s approximation for ties, GLRE , RGLRE . The four methods provided similar results among
patients with one tumor removed, but quite different results for those with multiple tumors removed.
For patients with only one tumor removed, the estimated hazard ratio (95% C.I.) of recurrence
(placebo/chemotherapy) was 1.28 (0.62, 2.66) using Weibull regression, 1.28 (0.61, 2.69) using the
Cox model with Efron’s approximation, 1.27 (0.61, 2.63) using GLRE and 1.27 (0.61, 2.68) using
RGLRE . For those with multiple tumors removed, the corresponding results were 2.37 (0.84, 6.70)
using Weibull regression, 1.96 (0.70, 5.51) using Cox model with Efron’s approximation, 3.50 (1.27,
9.85) using GLRE and 3.60 (1.27, 10.25) using RGLRE . As shown in Figure 3.4 (d), both GLRE
and RGLRE provided statistical evidence of a treatment difference based on the C.I. excluding one,
while Weibull regression and Cox model did not.
While Weibull and Cox regressions generated a narrower confidence interval, both of the methods
tend to have inflated type I error and lower coverage probability for 95% C.I. in small samples, as
shown in our simulation studies (Section 3.3). Therefore, our numerical results suggest RGLRE is
expected to be closer to the truth in this example.
Of note, in both real data examples, the estimated HR for GLR and GLRE was always closer to
one than that for RGLR and RGLRE . This is consistent with the simulation results in Section 3.3
which showed that GLR and GLRE tend to underestimate true hazard ratios that are greater than
one (and, by analogy, overestimate true hazard ratios that are less than one).
3.5. Discussion
Small sample studies of time-to-event outcomes are quite common in early phase clinical trials
and observational studies of rare diseases. Thus, it is important to have methods that provide
efficient hazard ratio estimation, control type I error and maintain confidence interval coverage in
small sample settings. In this chapter, we developed the RGLR statistic, and extended the method
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Figure 3.4: Bladder cancer data example: Kaplan-Meier survival curves and estimated hazard ratio
and 95% confidence interval comparing placebo and chemotherapy by number of tumors removed
at surgery.
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(a) and (c): one tumor removed at surgery. (b) and (d): multiple tumors removed at surgery. CoxE : Cox
regression using Efron’s method to adjust for tied events. Weibull: Weibull regression. GLRE : Generalized
log-rank approach using Efron’s method to adjust for tied events. RGLRE : Refined GLR approach using Efron’s
method to adjust for tied events. Data from Pagano and Gauvreau (2000).
to allow for ties. RGLR reduces bias while maintaining high relative efficiency versus the Cox
model by eliminating an unnecessary approximation in the GLR statistic. We also provided a more
intuitive development using inverse-variance weighting to estimate the nuisance parameters for
GLR. In addition, we have also demonstrated control of type I error rate and 95% C.I. coverage in
small samples for RGLR and explored the effect of misspecification of the underlying distribution on
parametric models. Through simulation studies, we have shown that the RGLR approach provides
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smaller bias relative to the Cox and true parametric models, and GLR, when the sample size per
group is around 40 or less and comparable performance for larger samples. RGLR was able to
consistently keep the type I error at or below the 5% nominal level in extensive simulations, while
the parametric and Cox models were observed to have an inflated type I error rate in small samples.
Furthermore, in real data applications, it is often challenging to know the true underlying distribution.
We have illustrated through simulations that when an incorrect distribution is used by a parametric
regression, it can result in large bias for the estimated hazard ratio. On the other hand, the RGLR
approach does not require any assumption about the true distribution, and consistently delivers a
very low bias with better efficiency relative to the Cox model. We recommend the use of RGLR in
the setting of two-group comparisons with survival outcomes in small samples over the commonly
used parametric and Cox models.
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CHAPTER 4
HAZARD RATIO ESTIMATION IN STRATIFIED PARALLEL DESIGNS UNDER
PROPORTIONAL HAZARDS
4.1. Introduction
In randomized clinical trials with a time-to-event endpoint, it is particularly important to incorporate
stratification when the risk of having the event of interest is affected by a certain prognostic factor,
such as race, gender, baseline disease severity, and so on. Several studies have shown that
omitting important covariates can lead to potentially spurious results (Bretagnolle and Huber-Carol,
1988; Ford and Norrie, 2002; Pocock et al., 2002; Schumacher, Olschewski, and Schmoor, 1987;
Struthers and Kalbfleisch, 1986). For example, Schumacher, Olschewski, and Schmoor (1987)
showed that the estimated hazard ratio is attenuated if a prognostic factor is omitted, and this result
is also confirmed by Bretagnolle and Huber-Carol (1988). A commonly used approach for analyzing
stratified trials with time-to-event outcomes is the stratified Cox proportional hazard model (Cox,
1972), which makes the assumption of proportional hazards within each stratum. It also imposes
an additional assumption that the hazard ratio is exactly the same across all strata, which seems
implausible in many practical settings. When there is a treatment by stratum interaction, i.e., the
hazard ratio differs by stratum, using the conventional stratified Cox model analysis can lead to a
biased and/or less efficient result.
To ensure unbiased and efficient results even when there exists a treatment by stratum interaction,
Mehrotra, Su, and Li (2012) proposed a two-step approach to allow for different hazard ratios across
strata. Their procedure entails fitting a Cox model separately for each stratum and then combining
the stratum-specific log hazard ratio estimates to obtain an estimate of the overall log hazard ratio;
the latter is defined later in this chapter and is presumed to be the parameter of interest. They
considered two weighting schemes: sample size (SS) weights and minimum risk (MR) weights
(Mehrotra and Railkar, 2000); both of these are described in the next section. The Mehrotra, Su,
and Li (2012) method was developed for large sample applications; however, many randomized
clinical trials involve relatively small samples (50-200 patients per treatment group) (Pocock, 1983).
It is also common at the discovery stage of a drug, for there to be known prognostic factors, for
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example, in settings such as cardiovascular disease or cancer, that may require a stratified de-
sign. In Chapter 3, we developed a method for improving hazard ratio estimation using a refined
generalized log-rank (RGLR) statistic in small randomized clinical trials without stratification, and
showed that it provides higher efficiency and smaller bias than the Cox proportional hazards model
analysis in small samples. In this chapter, we extend the RGLR statistic to handle stratification and
explore its performance in small samples. An additional contribution is the theoretical development
of a (remarkably accurate) approximation for the variance of the RGLR-based estimate of a log
hazard ratio. Section 4.2 includes details of the two-step RGLR approach for both the SS and MR
weighting schemes. In Section 4.3, we explore the relative performance of the competing methods,
namely the conventional stratified Cox model and two-step Cox model and corresponding two-step
RGLR analyses, through simulations. We then apply the methods to a real data example from a
colon cancer clinical trial in Section 4.4. Section 4.5 includes summary remarks and discussion.
4.2. Methods
Suppose there are i = 1, 2, . . . , S strata, and within stratum i, we randomize niA and niB subjects
to treatment A and B, respectively; by design, the ratio niA/niB is constant across strata. Denote
the sample size in stratum i as ni = niA+niB and total sample size as n =
∑S
i=1 ni. Within stratum
i, let ti1 < ti2 < · · · < tiki denote the ordered observed event times for the combined group across
treatments. Let βi denote the log hazard ratio in stratum i with θi = exp(βi) representing the hazard
ratio. If there is no treatment by stratum interaction, i.e., if βi = β for all i, there is no ambiguity
about the definition of the overall log hazard ratio. However, in the presence of an interaction, i.e, if
βi 6= β for at least one i and i∗, it is natural to define the target parameter as a population weighted
average of the βi’s, i.e., β¯ =
∑S
i=1 fiβi , where fi is the fraction of subjects in the target population
that are from stratum i (
∑S
i=1 fi = 1). The overall hazard ratio is defined as θoverall = exp(β¯).
The conventional stratified Cox model analysis assumes no treatment by stratum interaction, and
this can (and often does) result in a biased estimate of β¯. To allow for a potential treatment by
stratum interaction, we propose to use RGLR to estimate the log hazard ratio in each stratum, and
combine the stratum-specific point estimates using a weighted average to estimate the overall log
hazard ratio:
ˆ¯β =
S∑
i=1
wiβˆi. (4.1)
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Following Mehrotra, Su, and Li (2012), we consider two weighting schemes: sample size (SS) and
minimum risk (MR). Sample size weighting uses the sample size in each stratum relative to the
whole sample as the weight, i.e., wˆSSi = fi. While sample size weighting provides an unbiased
estimator of β¯, assuming simple random sampling, it can suffer from a needlessly large variance.
The MR weights proposed by Mehrotra and Railkar (2000) are intended to minimize mean-squared
error; for our stratified time-to-event setting, the weights are calculated as:
wˆMRi =
ai∑S
i=1 Vˆ
−1
i
− biVˆ
−1
i∑S
i=1 Vˆ
−1
i +
∑S
i=1 biβˆiVˆ
−1
i
·
∑S
i=1 βˆiai∑S
i=1 Vˆ
−1
i
, (4.2)
where bi = βˆi
∑S
i=1 Vˆ
−1
i −
∑S
i=1 βˆiVˆ
−1
i , ai = Vˆ
−1
i (1 + bi
∑S
i=1 βˆini/n), and Vˆi is the estimated
variance for βˆi.
To implement equation (4.2) we need to derive the variance of the stratum-specific RGLR estimate
of the log hazard ratio. In previous work (Chapter 3), we have shown that the (single-stratum) RGLR
statistic requires estimation of a nuisance parameter at time tj , pj =
∫ tj
tj−1
hB(x)dx, where hB(t) is
the hazard function for group B. Let random variables DjA and DjB denote the number of events at
time tj in group A and B, respectively, and let Dj = DjA +DjB . Let random variables RjA and RjB
denote the number of subjects at risk at time tj in group A and B, respectively, and rjA, rjB denote
the observed number of subjects at risk at time tj in group A and B. Under the assumption of no
tied event times, given dj , rjA, rjB , pj , β, DjA follows a non-central hypergeometric distribution, and
the conditional mean and variance of DjA is
EjA =
rjA(1− e−pjeβ )e−pj
rjA(1− e−pjeβ )e−pj + rjB(1− e−pj )e−pjeβ
(4.3)
VjA =
rjA(1− e−pjeβ )e−pjrjB(1− e−pj )e−pjeβ
[rjA(1− e−pjeβ )e−pj + rjB(1− e−pj )e−pjeβ ]2
. (4.4)
We showed in Chapter 3 that the nuisance parameter can be estimated using an unconditional ap-
proach. Let p˜ denote the estimated nuisance parameter vector, and define Sk(β, p˜) =
∑k
j=1(djA −
EjA) and Ik(β, p˜) =
∑k
j=1 VjA. Note that E[Sk(β, p˜)] = 0, and therefore, we can estimate the log
hazard ratio β by solving the moment equation Sk(β, p˜) = 0. Denote the moment log hazard ratio
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estimator by βˆRGLR. Then by the first order Taylor expansion, we have
βˆRGLR − β ∼= −Sk(β, p˜)
∂Sk(β,p˜)
∂β
, (4.5)
where
−∂Sk(β, p˜)
∂β
=
k∑
j=1
pje
βe−pje
−β
1− e−pjeβ VjA. (4.6)
As sample size gets large, pj → 0, and by L’Hopital’s rule, we have that limpj→0 pje
βe−pje
−β
1−e−pjeβ
= 1.
Thus,
−∂Sk(β, p˜)
∂β
∼=
k∑
j=1
VjA = Ik(β, p˜). (4.7)
Combining equations (4.5) and (4.7) gives us
√
Ik(β, p˜)(βˆ
RGLR − β) ∼= Sk(β, p˜)√
Ik(β, p˜)
. (4.8)
Since Sk(β, p˜) converges to the Cox score as n→∞, and p˜ goes to 0, an argument similar to that
in Andersen and Gill (1982) can be applied to show asymptotic normality of the RGLR estimator for
β. Specifically, by the Martingale Central Limit Theorem,
Sk(β, p˜)√
Ik(β, p˜)
D−→ N(0, 1). (4.9)
Therefore, denoting Vˆ (βˆRGLR, p˜) = I−1k (βˆ
RGLR, p˜) and combining equations (4.8) and (4.9), we
have
βˆRGLR − β√
Vˆ (βˆRGLR, p˜)
D−→ N(0, 1). (4.10)
And we conjecture the variance for the RGLR estimator to be
Vˆ (βˆRGLR, p˜) ≈
 k∑
j=1
rjA(1− e−p˜jeβˆ
RGLR
)e−p˜jrjB(1− e−p˜j )e−p˜jeβˆ
RGLR
[rjA(1− e−p˜jeβˆRGLR )e−p˜j + rjB(1− e−p˜j )e−p˜jeβˆRGLR ]2
−1 . (4.11)
With the variance formula now established for the RGLR estimator in each stratum, we can now
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calculate the MR weights using equation (4.2). For both weighting schemes, we do hypothesis
testing (H0 : β¯ = 0 vs. H1 : β¯ 6= 0), where ˆ¯βRGLR is the weighted sum of the S independent
stratum-specific estimates βˆRGLRi , as shown in equation (4.1). The variance of
ˆ¯βRGLR is calculated
as
Vˆ ( ˆ¯βRGLR) =
S∑
i=1
wˆ2i Vˆ (βˆ
RGLR
i , p˜). (4.12)
Then, confidence interval calculations can be done using Wald tests implied by equation (4.10). A
numerical study of the empirical accuracy of the variance formula (4.11) is provided in Appendix C.
4.3. Simulations
4.3.1. Simulation Set-up
We performed a simulation study to examine the bias, relative efficiency and nominal 95% confi-
dence interval (C.I.) coverage probability of the two-step RGLR using SS weights and MR weights,
and compared the performance of our proposed methods to the conventional stratified Cox propor-
tional hazards analysis and the two-step method of Mehrotra, Su, and Li (2012) in which stratum-
specific Cox model estimates are combined using SS weights or MR weights.
We considered the case of 2 strata and 4 strata in the simulation study. Usually, in the presence
of stratification, only the total number of subjects per group and randomization ratio (= 1 here) is
fixed by design. Therefore, we used a similar simulation set-up as Mehrotra and Railkar (2000)
and treated the number of subjects in each stratum as a random variable. Specifically, n pairs of
subjects were first assigned to stratum i with probability fi (
∑
fi = 1), where i = 1, 2 for 2 strata
and i = 1, 2, 3, 4 for 4 strata, and then, within each pair, one subject was randomly assigned to
treatment A and the other to treatment B with equal probability. Thereafter, for subject j in stratum
i and randomized to treatment q (q =A or B), we generated an entry time eijq from a uniform
distribution (0, T ). For 2 strata, survival times sijq for subject j under treatment A and treatment B in
stratum i were generated from Weibull (scale= λi/
√
θi, shape=2) and Weibull (scale=λi, shape=2)
respectively, where λ1 = 0.6, λ2 = 1.2. Note that the hazard function for Weibull (scale=λ, shape=γ)
is γxγ−1/λγ , so the hazard ratio of treatment A relative to B in stratum i is θi. The follow-up time for
a subject j randomized to treatment q in stratum i was tijq = min(sijq, T − eijq).
For 4 strata, we used the same procedure for generating number of subjects per stratum, entry time
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and survival time as described above for the two strata simulations. Survival time sijq for subject
j in stratum i under treatment A and B was generated from Weibull (scale=λi/
√
θi, shape=2) and
Weibull (scale=λi, shape=2), respectively, where now with λ1 = 0.6, λ2 = 0.8, λ3 = 1, and λ4 = 1.2.
We varied the stratum-specific relative frequency and true log hazard ratio, along with total sample
size and overall percentage censoring. Both equal (Scenario 1) and unequal stratum sizes (Sce-
nario 2) were considered. For 2 strata, we set f1 = f2 = 0.5 and f1 = 0.7, f2 = 0.3 for Scenario 1
and 2, respectively. For 4 strata, we set f1 = f2 = f3 = f4 = 0.25 and f1 = 0.15, f2 = 0.35, f3 =
0.35, f4 = 0.15 for Scenario 1 and 2, respectively. Under the null hypothesis, stratum-specific and
overall log hazard ratio was 0 in all cases. Under the alternative hypothesis, we considered two
settings: the same log hazard ratio across strata (Alt 1) and different log hazard ratios across strata
(Alt 2). The stratum-specific log hazard ratios in each scenario are summarized in Table 4.1; of
note, the overall log hazard ratio (β¯) was fixed at -0.7 in every case, which corresponds to an over-
all hazard ratio of exp(−0.7) = 0.5. Subjects per treatment group was varied as 50, 100 for 2 strata,
and 100, 200 for 4 strata. Two percentage censoring values were considered: 25% and 50%. 5000
replications were generated. Hypothesis testing was done at the α = 0.05 level. Results for bias
(under the null hypothesis), percent bias (under the alternative hypothesis), type I error rate, power,
relative efficiency and coverage probability for the 95% confidence interval (C.I.) for 2 and 4 strata
were obtained. Here, relative efficiency refers to 100 times the ratio of the mean squared error
(MSE) for the estimator of β¯ using the stratified Cox model relative to that using the given alter-
native method of estimation. Thus, relative efficiency estimators greater than 100% represent an
improvement over the stratified Cox model.
4.3.2. Simulation Results
Table 4.2 shows the results for the 2 strata case under the null hypothesis and the two alternative
hypotheses for both equal (Scenario 1) and unequal (Scenario 2) relative frequency in each stratum.
In Scenario 1, under the null hypothesis, all methods were associated with very small bias. Our
proposed two-step RGLR provided similar efficiency relative to the stratified Cox model, and higher
efficiency than the two-step Cox model method under both weighting schemes. Our proposed
method also controlled the type I error rate under 5% across all simulated scenarios, while both the
stratified Cox model and the two-step Cox model method had inflated type I error for 50 subjects per
treatment group and 25% censoring. Under the alternative hypothesis with no stratum by treatment
50
Table 4.1: True log hazard ratio in each stratum and overall under the null and alternative hypotheses.
2 strata
Scenario 1: Equal stratum sizes
Stratum Relative frequency Null (no interaction) Alt 1 (no interaction) Alt 2 (interaction)
1 0.5 0 -0.7 -0.2
2 0.5 0 -0.7 -1.2
Overall 0 -0.7 -0.7
Scenario 2: Unequal stratum sizes
Stratum Relative frequency Null (no interaction) Alt 1 (no interaction) Alt 2 (interaction)
1 0.7 0 -0.7 -0.4
2 0.3 0 -0.7 -1.4
Overall 0 -0.7 -0.7
4 strata
Scenario 1: Equal stratum sizes
Stratum Relative frequency Null (no interaction) Alternative 1 (no interaction) Alternative 2 (interaction)
1 0.25 0 -0.7 -0.3
2 0.25 0 -0.7 -0.4
3 0.25 0 -0.7 -0.8
4 0.25 0 -0.7 -1.3
Overall 0 -0.7 -0.7
Scenario 2: Unequal stratum sizes
Stratum Relative frequency Null (no interaction) Alternative 1 (no interaction) Alternative 2 (interaction)
1 0.15 0 -0.7 -0.3
2 0.35 0 -0.7 -0.4
3 0.35 0 -0.7 -0.8
4 0.15 0 -0.7 -1.65
Overall 0 -0.7 -0.7
Note: under all the alternative hypotheses for both 2 strata and 4 strata, the overall log hazard ratio β¯ is fixed at -0.7.
interaction (Alt 1), the stratified Cox is expected to have the best performance, and the two-step
RGLR provided very similar efficiency relative to the stratified Cox model. The two-step RGLR also
delivered a percentage bias less than 2% and maintained adequate coverage probability for the
95% C.I., while the stratified Cox model failed to do so under equal stratum sample size with 50
subjects per treatment and 25% censoring. When there was interaction between treatment and
stratum (Alt 2), the proposed two-step RGLR provided notably better efficiency and smaller bias
than all the other competing methods. Both the stratified and two-step Cox model methods had
issues with maintaining adequate 95% C.I. coverage probability in several simulated scenarios,
but the two-step RGLR with SS weights maintained adequate coverage probability throughout all
simulated settings. The two-step RGLR with MR weights also performed well but it failed to maintain
adequate coverage probability in the scenario with 100 subjects per treatment and 50% censoring.
With 100 subjects per treatment and 50% censoring, the two-step RGLR with SS weights delivered
42% higher efficiency than the stratified Cox model, with a percentage bias of 0.8%, comparing to
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-28.3% bias from the stratified Cox model. The performance of the methods for unequal relative
frequency in each stratum was similar to that for equal relative frequency described above.
Table 4.3 shows the results for the 4 strata case. Under both equal and unequal relative stratum
frequency, our two-step RGLR provided the smallest bias and higher relative efficiency compared
to the stratified Cox model. When there was a treatment by stratum interaction, the stratified Cox
model had a bias as large as -16.9%, while the two-step RGLR controlled the bias under 8%. In
terms of type I error, the stratified and two-step Cox model methods had inflated type I error issues
with smaller sample sizes (100 subjects per treatment group with 25% and 50% censoring under
Scenario 1), while our two-step RGLR did not. In terms of coverage probability, the two-step RGLR
maintained adequate coverage probability for 95% C.I. throughout all scenarios, while the stratified
Cox model failed to do so under several scenarios.
We also examined power among the methods. Table 4.4 shows the results for 100 subjects per
treatment with 50% censoring for 2 strata and 4 strata cases; results under other simulated sce-
narios (not shown) did not provide additional insights and are hence not shown. When there was
no interaction between treatment and stratum, our two-step RGLR provided similar power as the
stratified Cox model. When there is interaction, using two-step RGLR delivered a power increase
of at least 5 percentage points relative to the stratified Cox model. While the two-step Cox model
method seemed to have slightly better power than the two-step RGLR, the former also had inflated
type I error rate while our two-step RGLR did not.
4.4. Application
We apply the stratified Cox model, the Mehrotra, Su, and Li (2012)’s two-step Cox model method
and our proposed two-step RGLR method, with both two-step methods using sample size (SS) and
minimum risk (MR) weights, to a clinical trial involving resected colon cancer (Lin et al., 2016). The
data set included 154 patients with stage C colon cancer who were randomized to receive placebo
or levamisole combined with fluorouracil therapy, with 77 patients in each group. The outcome
of interest was overall survival. Patients were stratified by the number of lymph nodes involved
(≤ 4 vs >4). Table 4.5 summarizes the results from applying all the methods. The stratified Cox
model provided an estimated overall hazard ratio (therapy:placebo) of exp(−0.64) = 0.53 (95% C.I.:
0.31, 0.90), with a p-value of 0.021. On the other hand, the two-step Cox and two-step RGLR,
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Table 4.2: Bias (% bias), percent ratio of MSE relative to one-step stratified Cox model and coverage probability for 95%
C.I. for overall log hazard ratio β¯ for 2 strata based on 5000 simulations.
Scenario 1: Equal stratum sizes (f1 = f2 = 0.5)
Null Alt 1 (no interaction) Alt 2 (interaction)
Censoring N /trt Method Bias %RE Cov %Bias %RE Cov %Bias %RE Cov
25% 50 Stratified Cox -0.001 100 [94.2] 1.8 100 94.6 -12.7 100 [92.8]
2-step Cox (SS wts) -0.001 95 [93.9] 3.7 94 [94.0] 4.2 93 [94.1]
2-step RGLR (SS wts) -0.001 102 94.7 0.1 101 95.0 0.5 100 94.8
2-step Cox (MR wts) -0.001 97 [93.9] 2.8 97 [94.3] 0.7 97 [94.3]
2-step RGLR (MR wts) -0.001 105 94.9 -0.8 104 95.1 -3.0 103 94.7
100 Stratified Cox -0.001 100 95.0 0.9 100 94.8 -13.5 100 [90.1]
2-step Cox (SS wts) -0.002 97 94.8 1.8 97 94.5 2.5 110 [94.0]
2-step RGLR (SS wts) -0.002 102 95.3 -0.2 100 95.0 0.5 115 94.4
2-step Cox (MR wts) -0.001 99 94.8 1.54 98 94.5 0.5 113 [94.1]
2-step RGLR (MR wts) -0.001 103 95.3 -0.6 102 95.0 -1.5 117 94.4
50% 50 Stratified Cox 0.000 100 94.4 2.0 100 94.7 -27.1 100 [89.8]
2-step Cox (SS wts) 0.001 86 94.7 4.3 85 95.1 4.8 97 95.7
2-step RGLR (SS wts) 0.001 93 95.6 0.4 93 96.0 1.0 106 96.3
2-step Cox (MR wts) 0.000 94 94.4 2.8 93 94.8 -4.3 109 94.5
2-step RGLR (MR wts) 0.000 102 95.5 -1.0 102 95.3 -8.3 116 94.8
100 Stratified Cox -0.001 100 95.0 1.1 100 94.9 -28.3 100 [82.7]
2-step Cox (SS wts) -0.003 89 94.8 2.4 89 94.6 2.9 135 94.9
2-step RGLR (SS wts) -0.003 93 95.3 0.3 93 95.1 0.8 142 95.2
2-step Cox (MR wts) -0.002 95 94.7 1.7 95 94.6 -3.0 141 [93.5]
2-step RGLR (MR wts) -0.002 99 95.1 -0.4 99 94.9 -5.2 145 [93.6]
Scenario 2: Unequal stratum sizes (f1 = 0.7, f2 = 0.3)
Null Alt 1 (no interaction) Alt 2 (interaction)
Censoring N /trt Method Bias %RE Cov %Bias %RE Cov %Bias %RE Cov
25% 50 Stratified Cox 0.002 100 [94.2] 1.6 100 94.6 -12.5 100 [93.4]
2-step Cox (SS wts) 0.003 93 [94.2] 3.5 92 94.3 4.6 91 [94.2]
2-step RGLR (SS wts) 0.002 101 94.9 0.0 99 95.0 0.0 100 94.9
2-step Cox (MR wts) 0.002 96 [94.3] 2.6 96 94.5 0.2 98 [94.2]
2-step RGLR (MR wts) 0.002 104 94.7 -0.9 103 95.0 -4.4 105 94.4
100 Stratified Cox 0.003 100 95.3 0.6 100 95.5 -12.1 100 [91.3]
2-step Cox (SS wts) 0.002 96 95.0 1.5 96 95.3 2.5 106 94.4
2-step RGLR (SS wts) 0.002 101 95.6 -0.5 100 95.7 0.0 112 94.8
2-step Cox (MR wts) 0.002 98 95.0 1.1 98 95.4 0.1 111 94.4
2-step RGLR (MR wts) 0.002 103 95.5 -0.9 102 95.5 -2.4 115 94.7
50% 50 Stratified Cox -0.001 100 95.0 1.5 100 95.0 -21.7 100 [90.0]
2-step Cox (SS wts) -0.003 87 95.2 3.2 89 95.0 -0.3 104 95.9
2-step RGLR (SS wts) -0.003 95 96.1 -0.5 97 95.8 -4.7 113 96.2
2-step Cox (MR wts) -0.002 95 95.0 2.0 96 94.7 -8.4 112 [94.3]
2-step RGLR (MR wts) -0.002 103 95.7 -1.6 104 95.5 -12.8 116 94.4
100 Stratified Cox 0.004 100 95.2 0.4 100 95.1 -21.0 100 [87.9]
2-step Cox (SS wts) 0.004 88 95.0 1.3 89 94.9 4.1 106 95.5
2-step RGLR (SS wts) 0.004 92 95.7 -0.7 93 95.3 1.4 113 95.9
2-step Cox (MR wts) 0.004 94 94.9 0.8 95 94.8 -2.3 116 [94.3]
2-step RGLR (MR wts) 0.003 99 95.3 -1.2 99 95.3 -5.1 121 94.4
Trt=treatment group; bias is reported under the null hypothesis, and percentage bias is reported under the alternative hypothesis. %RE
is 100 times MSE of stratified Cox/MSE of competing method. Coverage probability more than Z0.975 standard errors below 95% is
in square brackets. Each 2-step method uses a weighted average of stratum-specific log hazard ratio estimates; SS wts=sample size
weights, MR wts=minimum risk weights.
for both SS and MR weights, provided a non-significant p-value (>0.05). The estimated hazard
ratio in stratum 1 from using Cox and RGLR were exp(−0.27) = 0.76 and exp(−0.26) = 0.77,
respectively, with corresponding estimates of the hazard ratio in stratum 2 being exp(−1.16) = 0.31
and exp(−1.14) = 0.32, respectively. The Kaplan-Meier curves by stratum in Figure 4.1 appear
to support the differential treatment effect across the two strata, i.e, they suggest evidence of a
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Table 4.3: Bias (% bias), percent ratio of MSE relative to one-step stratified Cox model and coverage probability for 95%
C.I. for overall log hazard ratio β¯ for 4 strata based on 5000 simulations.
Scenario 1: Equal stratum sizes (f1 = f2 = f3 = f4 = 0.25)
Null Alt 1 (no interaction) Alt 2 (interaction)
Censoring N /trt Method Bias %RE Cov %Bias %RE Cov %Bias %RE Cov
25% 100 Stratified Cox 0.000 100 94.8 0.7 100 95.2 -8.5 100 [93.1]
2-step Cox (SS wts) 0.001 93 [94.0] 3.3 91 94.6 3.6 92 [94.0]
2-step RGLR (SS wts) 0.001 101 94.8 -0.3 99 95.3 -0.1 100 94.8
2-step Cox (MR wts) 0.001 95 [94.1] 2.6 94 94.9 1.8 95 [94.1]
2-step RGLR (MR wts) 0.001 103 94.9 -1.0 101 95.4 -1.9 102 94.6
200 Stratified Cox 0.001 100 94.8 0.4 100 95.2 -9.2 100 [91.6]
2-step Cox (SS wts) 0.001 97 94.7 1.6 96 94.9 1.6 114 [94.2]
2-step RGLR (SS wts) 0.001 102 95.2 -0.4 100 95.4 -0.4 119 94.7
2-step Cox (MR wts) 0.001 98 94.7 1.3 97 95.0 0.6 116 [94.1]
2-step RGLR (MR wts) 0.001 103 95.1 -0.7 101 95.3 -1.5 119 94.4
50% 100 Stratified Cox -0.001 100 94.9 1.1 100 94.7 -16.0 100 [90.7]
2-step Cox (SS wts) -0.001 87 94.5 4.1 85 94.5 4.3 94 94.9
2-step RGLR (SS wts) -0.001 94 95.4 0.2 93 95.3 0.4 104 95.7
2-step Cox (MR wts) -0.001 92 [94.3] 2.9 90 [94.2] 0.2 102 [93.9]
2-step RGLR (MR wts) -0.001 99 95.3 -1.0 99 94.9 -3.8 110 94.6
200 Stratified Cox 0.000 100 94.9 0.4 100 95.2 -16.9 100 [86.4]
2-step Cox (SS wts) -0.001 94 94.9 1.9 91 94.8 2.2 129 95.0
2-step RGLR (SS wts) -0.001 98 95.4 -0.3 96 95.4 0.1 136 95.3
2-step Cox (MR wts) -0.001 96 94.7 1.3 95 94.6 -0.5 134 [94.3]
2-step RGLR (MR wts) -0.001 100 95.1 -0.8 99 95.1 -2.6 138 94.5
Scenario 2: Unequal stratum sizes (f1 = 0.15, f2 = 0.35, f3 = 0.35, f4 = 0.15)
Null Alt 1 (no interaction) Alt 2 (interaction)
Censoring N /trt Method Bias %RE Cov %Bias %RE Cov %Bias %RE Cov
25% 100 Stratified Cox 0.000 100 95.1 0.8 100 95.6 -9.8 100 [92.4]
2-step Cox (SS wts) 0.000 93 94.2 3.5 91 94.9 3.4 95 [94.3]
2-step RGLR (SS wts) 0.000 101 95.0 -0.1 99 95.6 -0.6 104 94.9
2-step Cox (MR wts) 0.000 95 94.4 2.6 94 95.2 1.2 100 [94.3]
2-step RGLR (MR wts) 0.000 103 95.1 -0.9 101 95.5 -2.8 107 94.6
200 Stratified Cox -0.000 100 95.5 0.5 100 95.2 -9.8 100 [91.1]
2-step Cox (SS wts) -0.001 97 95.2 1.7 96 94.9 2.0 113 94.9
2-step RGLR (SS wts) -0.000 101 95.6 -0.2 100 95.2 -0.2 119 95.3
2-step Cox (MR wts) -0.000 98 95.1 1.4 97 94.8 0.9 116 94.8
2-step RGLR (MR wts) -0.000 102 95.8 -0.6 101 95.4 -1.4 120 95.1
50% 100 Stratified Cox 0.002 100 95.0 0.5 100 95.3 -16.8 100 [90.9]
2-step Cox (SS wts) 0.002 91 94.8 3.4 89 95.2 -0.3 112 95.4
2-step RGLR (SS wts) 0.002 98 95.7 -0.4 97 95.9 -4.2 119 95.9
2-step Cox (MR wts) 0.002 95 94.6 2.2 94 94.9 -4.1 116 94.7
2-step RGLR (MR wts) 0.002 102 95.4 -1.6 102 95.6 -8.0 119 94.7
200 Stratified Cox 0.001 100 95.0 0.2 100 95.4 -16.5 100 [86.8]
2-step Cox (SS wts) 0.002 93 94.9 1.7 93 95.2 1.9 128 95.4
2-step RGLR (SS wts) 0.002 97 95.3 -0.4 97 95.4 -0.4 136 95.5
2-step Cox (MR wts) 0.002 96 94.6 1.2 96 95.0 -0.9 134 94.4
2-step RGLR (MR wts) 0.002 100 95.1 -0.9 100 95.2 -3.2 138 94.7
Trt=treatment group; bias is reported under the null hypothesis, and percentage bias is reported under the alternative hypothesis. %
RE is 100 times MSE of stratified Cox/MSE of competing method. Coverage probability more than Z0.975 standard errors below 95% is
in square brackets. Each 2-step method uses a weighted average of stratum-specific log hazard ratio estimates; SS wts=sample size
weights, MR wts=minimum risk weights.
treatment by stratum interaction. The overall hazard ratio from the two-step RGLR with SS and MR
weights was estimated to be exp(−0.50) = 0.61 (95% C.I.: 0.34, 1.06) and exp(−0.53) = 0.59 (95%
C.I.: 0.83, 1.02), respectively.
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Table 4.4: Power comparisons among the competing methods based on 100 subjects per treatment group and 50% censor-
ing with 5000 simulations for 2 strata (top panel) and 4 strata (bottom panel).
2 strata
Scenario 1: f1 = f2 = 0.5 Scenario 2: f1 = 0.7, f2 = 0.3
Method Alt 1 (no interaction) Alt 2 (interaction) Alt 1 (no interaction) Alt 2 (interaction)
Stratified Cox 92.5 [66.8] 96.2 [80.5]
2-step Cox (SS wts) 90.4 86.2 94.9 90.7
2-step RGLR (SS wts) 89.8 85.0 94.4 89.5
2-step Cox (MR wts) 91.8 [84.2] 95.6 [89.9]
2-step RGLR (MR wts) 91.3 [83.1] 95.1 88.9
4 strata
Scenario 1: f1 = f2 = f3 = f4 = 0.25 Scenario 2: f1 = 0.15, f2 = 0.35, f3 = 0.35, f4 = 0.15
Method Alt 1 (no interaction) Alt 2 (interaction) Alt 1 (no interaction) Alt 2 (interaction)
Stratified Cox 91.2 78.8 90.8 [80.6]
2-step Cox (SS wts) 89.8 86.9 89.9 87.3
2-step RGLR (SS wts) 88.5 85.4 88.4 85.6
2-step Cox (MR wts) [90.9] [87.2] 90.8 87.4
2-step RGLR (MR wts) 89.7 85.5 89.3 85.6
Square brackets indicate the case where the coverage probability is more than Z0.975 standard errors below 95%.
Table 4.5: Log hazard ratio estimates for the Colon cancer data example in Lin et al. (2016).
N(%) Stratified Cox 2-step Cox (SS wts) 2-step RGLR (SS wts) 2-step Cox (MR wts) 2-step RGLR (MR wts)
Stratum 1 βˆ1 112 (73%) -0.64* -0.27 -0.26 -0.27 -0.26
Stratum 2 βˆ2 42 (27%) -0.64* -1.16 -1.14 -1.16 -1.14
ˆ¯β -0.64* -0.51 -0.50 -0.54 -0.53
95% C.I. (-1.18, -0.10) (-1.08, 0.05) (-1.07, 0.06) (-1.10, 0.02) (-1.09, 0.02)
P-value 0.021 0.075 0.080 0.057 0.060
*The stratified Cox model assumes β1 = β2; these are the implied stratum-specific estimates based on the overall estimate.
4.5. Discussion
The stratified Cox model is often used to analyze stratified randomized clinical trials with time-to-
event data. However, the assumption of equal hazard ratios across strata may not be true in real
applications. Therefore, it is important to develop methods to handle a treatment by stratum inter-
action, especially in relatively small stratified trials with low power to detect a treatment by stratum
interaction. In this work, we proposed a two-step RGLR approach in which we estimate stratum-
specific log hazard ratios using the RGLR approach and combine them across strata using SS or
MR weights. Through simulation studies, we have shown that the two-step RGLR provides notably
smaller bias and smaller mean squared error than the conventional stratified Cox model when there
is a treatment-by-stratum interaction, with similar performance when there is no interaction. The
stratified Cox model is subject to have inflated type I error in small samples, while the two-step
RGLR does not. The stratified Cox model also has trouble with CI under-coverage in small sam-
ples, while the two-step RGLR with SS weights does not and with MR weights generally does not.
The two-step RGLR method also delivers much higher power than the stratified Cox model when
the hazard ratio differs across strata while suffering no material power loss in other cases. Finally,
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Figure 4.1: Kaplan-Meier survival curves by treatment group; (a) is for stratum 1 (b) is stratum 2.
the proposed method has similar or better performance than the two-step method of Mehrotra, Su,
and Li (2012) in terms of bias and mean squared error; this to be be expected because within each
stratum, the RGLR estimator outperforms the Cox model estimator in small to moderate sample
sizes, notably so in small samples.
The two-step RGLR removes the restrictive assumption of equal hazard ratios across strata in the
stratified Cox model analysis, and outperforms the stratified Cox model when there is an interaction
between treatment and stratum. More importantly, the two-step RGLR also provides an estimated
stratum-specific hazard ratio, while the stratified Cox model only provides an estimated overall
hazard ratio. As shown in the colon cancer example, when the hazard ratio is different across
stratum, using the two-step RGLR can provide additional insight into the difference across strata,
while the stratified Cox model does not.
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CHAPTER 5
DISCUSSION
5.1. Summary
In this dissertation, we developed methods for analyzing time-to-event data in small samples un-
der both crossover and parallel designs. In Chapter 2, we examined situations in 2×2 crossover
trials with time-to-event endpoints and proposed a regression-based method to incorporate base-
line information to improve the efficiency. We proposed to use multiple imputation with multiple
candidate models, to impute censored outcomes in post-treatment. In each imputed data set, we
applied ANCOVA on the log-transformed event times, with the difference in period-specific base-
line measurement as a covariate, to estimate the log treatment-ratio of geometric means. Finally,
we used frequentist model averaging with AIC weighting and Rubin’s combination rule for multiple
imputation to combine the results from the candidate models. We compared our method to existing
methods, the H-R test and stratified Cox model, and showed through extensive numerial studies
that our method was able to deliver more or as efficient results. Additionally, we were also able to
provide a point estimate on the ratio of geometric means between the two treatments, while H-R
test fails to do so. For symmetric distributions, the ratio of geometric means is approximately equal
to the ratio of medians, which is a commonly used measure for time-to-event outcomes. Therefore,
we were able to provide a meaningful estimate of the treatment effect. For ease of illustration, we
used the log-normal and Weibull as two candidate models to impute the censored values, because
they are flexible to capture a variety of distribution shapes for in survival data. Even by using only
two models, we delivered higher power than the stratified Cox model, and more or similar power
as H-R test, even when the true underlying distribution is not included in the candidate model. In
practice, the number and choice of candidate models can be changed to fit the anticipated potential
distributions for a given setting, and we believe that adding more candidate models will only improve
the efficiency of our proposed method more.
In Chapter 3, we focused on improving hazard ratio estimation in small parallel clinial trials in the
setting of proportional hazards. We proposed a refined generalized log-rank (RGLR) statistic that
replaced the estimation of nuisance parameters with the exact counterpart in the original general-
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ized log-rank (GLR) statistic by Mehrotra and Roth (2001). We also provided a more intuitive de-
velopment for the nuisance parameter estimation using inverse-variance weighting in GLR statistic.
We showed that RGLR reduced bias significantly, compared to GLR, Cox and parametric mod-
els, and maintained high relative efficiency versus the Cox model in small samples. Our proposed
RGLR also controlled the type I error rate and maintained the nominal coverage probability in small
samples, while Cox and parametric models were subject to type I error inflation when there were
fewer than 40 subjects per group. Additionally, the true underlying distribution is often unknown in
real data applications, and thus, parametric models are subject to misspecification. We showed
that our proposed method was not subject to misspecification, and consistently delivered low bias
and higher efficiency relative to the Cox model.
In Chapter 4, we further extended the RGLR statistic to allow for stratification factors and proposed
the two-step RGLR method, in which stratum-specific log hazard ratio was first obtained using
RGLR and the overall log hazard ratio was combined using two different weighting schemes, sample
size and minimum risk weights. In addition, we also developed a variance estimator for the RGLR
estimate of the log hazard ratio and demonstrated its accuracy through simulation studies. We
showed that the two-step RGLR method provided notably smaller bias and mean squared error
than the conventional stratified Cox model in the presence of a treatment by stratum interaction,
and delivered similar performance when there was no interaction. Compared to the two-step Cox
model method by Mehrotra, Su, and Li (2012), our two-step RGLR also had a similar or better
performance in terms of bias and mean squared error in small samples; the former was developed
for larger sample sizes while the RGLR approach provided notably better performance in small
samples as shown in Chapter 3. The stratified and two-step Cox model methods also suffered from
inflated type I error, while our two-step RGLR did not. When there was an interaction between
treatment and stratum, the two-step RGLR was able to deliver higher power than the stratified Cox
model.
5.2. Future Directions
5.2.1. Non-parametric ANCOVA
There are several interesting directions to consider for future study of crossover studies with time-
to-event outcomes. The method we proposed in Chapter 2 used parametric ANCOVA to estimate
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the treatment effect between the two treatments. We can also use non-parametric ANCOVA to
potentially further improve the efficiency of our proposed method. Parametric ANCOVA still poses
some underlying normality assumptions on the event times, while non-parametric approach re-
moves the assumption completely. It is expected that when the underlying normality assumption is
truly not met, by non-parametric ANCOVA can provide a more robust and efficient result. However,
the point estimator directly from non-parametric ANCOVA does not provide a meaningful interpre-
tation. Thus, we also need to incorporate a method that can invert the test from non-parametric
approach to have a meaningful point estimator on treatment effect.
5.2.2. Baseline Censoring
In Chapter 2, we assumed no censoring in the baseline measurement, and only imputed the cen-
sored values in post-treatment. However, it is possible that in some real data applications, censored
values can also be observed in the baseline measurement. Therefore, we are interested in loosing
this assumption, and extending our method to allow for censoring in the baseline measurement.
One possible direction is to use other characteristics of the subjects, such as gender, age and sex,
to first impute the censored baseline measurements, to have complete data in baseline, and then
proceed with the method as proposed.
5.2.3. Comparison to Lin et al. (2016) Methods for Stratified Trials
Lin et al. (2016) recently proposed a solution to estimating a confidence interval based on the
score test statistic from the stratified Cox model, and proposed to handle tied event times using
the Breslow (1974) method. They assumed a constant hazard ratio across the strata and used
a sub-optimal approach to handle tied event times. On contrary, we proposed a two-step RGLR
method for stratified clinical trials with time-to-event outcomes in Chapter 4, and proposed to use
Efron’s method for handling ties in the RGLR method in Chapter 3. We allowed for a treatment
by stratum interaction and demonstrated better performance for the two-step RGLR compared the
conventional stratified Cox model. Thus, we are interested in comparing our proposed two-step
RGLR method to the Lin et al. (2016) method.
59
APPENDIX A
SUPPLEMENTARY MATERIALS FOR CHAPTER 2
A.1. Supplementary Figure
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Figure A.1: Density curves for survival time under lognormal(µ = 0, σ = 1), where µ and σ denotes
the mean and standard deviation on the log scale, exponential(rate=0.5) and gamma(shape=2,
scale=0.7), respectively.
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A.2. Supplementary Tables
Table A.1: True θ values used in the simulation study under the alternative hypothesis for each
combination of distribution, covariance structure, ρ¯, censoring and sample size per sequence (θ = 1
under the null hypothesis.)
ρ = 0.5 ρ = 0.7
10% Censoring 50% Censoring 10% Censoring 50% Censoring
Distribution
PPPPPPPΣ
N/seq 12 24 48 12 24 48 12 24 48 12 24 48
Log-normal CS 1.85 1.6 1.4 1.95 1.7 1.5 1.65 1.5 1.3 1.9 1.6 1.35
AR(1) 1.85 1.6 1.4 1.95 1.7 1.5 1.65 1.5 1.3 1.9 1.6 1.35
EP 1.85 1.6 1.4 1.95 1.7 1.4 1.6 1.5 1.25 1.75 1.45 1.35
Exponential CS 2 1.7 1.5 2.1 1.8 1.6 1.8 1.5 1.35 2 1.7 1.5
AR(1) 2 1.7 1.5 2.1 1.8 1.6 1.8 1.5 1.3 2 1.7 1.4
EP 2 1.7 1.4 2.1 1.8 1.6 1.8 1.5 1.3 2 1.7 1.4
Gamma CS 2.7 1.8 1.5 3.7 2.2 1.6 2.2 1.5 1.35 3 1.8 1.5
AR(1) 2.7 1.8 1.5 3.7 2.2 1.6 2.2 1.5 1.35 3 1.8 1.5
EP 2.7 1.8 1.4 3.7 2.2 1.6 2 1.5 1.3 3 1.8 1.4
CS: compound symmetry covariance structure. AR(1): first-order autoregressive covariance structure. EP: equipredicabil-
ity covariance structure. ρ¯: mean pairwise correlation.
Table A.2: Power (%) for the hierarchical rank test (H-R), stratified Cox model with baseline adjust-
ment (SCB) and proposed multiple imputation with model averaging and ANCOVA (MIMA) under
log-normal distribution based on 5000 simulations.
ρ = 0.5 ρ = 0.7
10% Censoring 50% Censoring 10% Censoring 50% Censoring
Σ
XXXXXXXXXXMethod
N/seq 12 24 48 12 24 48 12 24 48 12 24 48
CS H-R 69.3 78.4 83.1 71.6 76.8 79.6 72.7 86.7 81.5 84.4 87.9 80.3
SCB NC 69.8 74.3 NC NC 71.3 NC 78.9 73.0 NC 77.5 73.0
MIMA 76.3 84.9 89.4 65.8 77.8 86.3 80.2 92.1 88.7 75.7 87.2 80.9
AR(1) H-R 68.6 79.2 80.8 69.1 77.4 76.9 71.9 85.7 80.0 82.6 83.7 77.9
SCB NC 72.5 74.6 NC 65.4 69.8 NC 80.0 73.7 NC 69.4 71.9
MIMA 80.4 89.5 92.0 67.7 79.9 85.8 86.0 95.9 92.3 77.7 84.5 84.6
EP H-R 70.2 79.1 75.1 70.9 76.3 79.8 68.1 73.4 67.9 82.8 66.9 78.6
SCB NC 71.7 67.2 NC NC 72.4 NC NC 68.9 NC NC 75.9
MIMA 83.1 91.1 87.3 69.8 81.7 89.8 94.2 84.6 94.8 85.1 78.9 93.5
NC: Non-convergence issues. CS: compound symmetry covariance structure. AR(1): first-order autoregressive covariance
structure. EP: equipredicability covariance structure. ρ¯: mean pairwise correlation. True values of θ used under the alternative
hypothesis are provided in Table A.1.
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Table A.3: Power (%) for the hierarchical rank test (H-R), stratified Cox model with baseline adjust-
ment (SCB) and proposed multiple imputation with model averaging and ANCOVA (MIMA) under
exponential distribution based on 5000 simulations.
ρ = 0.5 ρ = 0.7
10% Censoring 50% Censoring 10% Censoring 50% Censoring
Σ
XXXXXXXXXXMethod
N/seq 12 24 48 12 24 48 12 24 48 12 24 48
CS H-R 80.0 86.8 92.0 67.4 76.4 85.7 84.8 84.2 88.0 76.8 81.4 86.7
SCB NC 69.7 78.5 NC 61.8 75.1 NC 67.2 72.9 NC 69.1 76.4
MIMA 70.1 78.6 85.2 63.3 78.6 89.7 76.6 76.8 81.5 74.0 86.6 93.2
AR(1) H-R 78.5 86.6 91.7 66.4 82.9 83.6 82.3 82.9 87.0 74.0 82.6 85.4
SCB NC 72.1 78.6 NC 74.6 73.7 NC 68.7 73.3 NC 69.6 76.7
MIMA 75.2 82.8 88.3 67.0 89.0 92.3 80.8 82.8 86.4 78.9 90.9 95.2
EP H-R 78.8 87.0 92.4 84.7 77.2 85.2 84.2 84.8 77.3 75.0 82.7 71.0
SCB NC 73.2 80.0 NC 64.9 75.5 NC 75.4 71.3 NC NC 64.1
MIMA 75.3 84.2 89.7 92.2 84.6 93.5 92.9 93.6 91.5 89.4 96.6 93.4
NC: Non-convergence issues. CS: compound symmetry covariance structure. AR(1): first-order autoregressive covariance
structure. EP: equipredicability covariance structure. ρ¯: mean pairwise correlation. True values of θ used under the alternative
hypothesis are provided in Table A.1.
Table A.4: Power (%) for the hierarchical rank test (H-R), stratified Cox model with baseline adjust-
ment (SCB) and proposed multiple imputation with model averaging and ANCOVA (MIMA) under
gamma distribution based on 5000 simulations.
ρ = 0.5 ρ = 0.7
10% Censoring 50% Censoring 10% Censoring 50% Censoring
Σ
XXXXXXXXXXMethod
N/seq 12 24 48 12 24 48 12 24 48 12 24 48
CS H-R 87.5 86.3 87.7 86.9 87.8 89.2 91.3 78.2 86.9 92.5 86.0 88.9
SCB NC 71.3 72.4 NC 76.2 78.6 NC 61.7 72.3 NC 74.0 79.4
MIMA 82.7 82.2 83.2 78.7 86.2 89.2 87.8 73.5 82.5 85.9 84.7 88.7
AR(1) H-R 86.9 85.7 88.0 89.0 92.0 87.4 90.8 77.7 86.3 91.7 84.4 84.3
SCB NC 72.1 74.9 NC 82.7 78.3 NC 63.9 74.1 NC 74.0 76.0
MIMA 86.2 85.6 87.2 84.8 92.9 90.6 91.8 80.8 88.4 89.3 87.1 88.9
EP H-R 87.6 86.1 79.8 88.2 86.9 88.1 85.3 78.7 75.1 91.4 82.3 78.7
SCB NC 74.6 66.1 NC 77.0 80.2 NC 72.2 69.6 NC 72.8 74.7
MIMA 87.0 87.0 80.8 86.5 89.4 92.7 95.9 92.5 90.8 93.0 92.7 92.4
NC: Non-convergence issues. CS: compound symmetry covariance structure. AR(1): first-order autoregressive covariance
structure. EP: equipredicability covariance structure. ρ¯: mean pairwise correlation. True values of θ used under the alternative
hypothesis are provided in Table A.1.
A.3. R code for Data Application Example
###load packages
library(survival)
library(perm)
library(truncdist)
library(mvtnorm)
######read in data
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data<-read.csv(’treadmill dataset.csv’,header=T)
###############################
##########H-R Test#############
###############################
n=40
t1=data$p1 ###post-trt time in period 1
t2=data$p2 ###post-trt time in period 2
delta1=data$deltap1 ###post-trt censoring indicator in period 1
delta2=data$deltap2 ###post-trt censoring indicator in period 2
hr_rank=rep(NA,n)
#patients with only one event get extreme ranks
ind_p2=which(delta1==0&delta2==1)
n01=length(ind_p2)
t2_sorted=sort(t2[ind_p2],index.return=T)
ind_p2rank=ind_p2[t2_sorted$ix]
hr_rank[ind_p2rank]=1:n01
ind_p1=which(delta1==1&delta2==0)
n10=length(ind_p1)
t1_sorted=sort(t1[ind_p1],index.return=T,decreasing=T)
ind_p1rank=ind_p1[t1_sorted$ix]
hr_rank[ind_p1rank]=(n-n10+1):n
#patients with events in both periods have less extreme ranks
ind_both1=which(delta1==1&delta2==1&t1>t2)
n11_1=length(ind_both1)
diff1=sort(t1[ind_both1]-t2[ind_both1],index.return=T,decreasing=T)
both1rank=ind_both1[diff1$ix]
hr_rank[both1rank]=(n01+1):(n01+n11_1)
ind_both2=which(delta1==1&delta2==1&t1<=t2)
n11_2=length(ind_both2)
diff2=sort(t2[ind_both2]-t1[ind_both2],index.return=T)
both2rank=ind_both2[diff2$ix]
hr_rank[both2rank]=(n-n10-n11_2+1):(n-n10)
#patients with no events in either period have the average rank
ind_neither=which(delta1==0&delta2==0)
hr_rank[ind_neither]=(n01+n11_1+1+n-(n10+n11_2))/2
##two group wilcoxon signed rank test
pval=permTS(hr_rank[1:(n/2)],hr_rank[(n/2+1):n],exact=T,
control=permControl(setSEED=FALSE))$p.value
###############################
####Stratified Cox#############
###############################
####transform the data to long format
data_long=reshape(data,
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varying=c("deltab1","b1","deltap1","p1",
"deltab2","b2","deltap2","p2"),
v.names=c("delta","event_time"),
timevar=c("b1","p1","b2","p2"),
times=c(1,2,3,4),
new.row.names=1:(4*n),
direction="long")
data_long <- data_long[order(data_long$id),]
data_long$trt_ind=c(rep(c(NA,0,NA,1),n/2),rep(c(NA,1,NA,0),n/2))
data_long$period_ind=rep(c(0,0,1,1),n)
model_scb=coxph(Surv(event_time[time==2|time==4],delta[time==2|time==4])
~trt_ind[time==2|time==4]+period_ind[time==2|time==4]
+event_time[time==1|time==3]+strata(id[time==2|time==4]),
data=data_long)
###############################
#####Proposed Method###########
###############################
tau=10 ##end of time
###period 1
num_missing_p1=length(which(data$deltap1==0))
##period 2
num_missing_p2=length(which(data$deltap2==0))
#####BA sequence, period 1
id_BA_p1=which(data$deltap1==0&data$seq=="ba")
num_missing_BA_p1=length(id_BA_p1)
#####AB sequence, period 2
id_AB_p2=which(data$deltap2==0&data$seq=="ab")
num_missing_AB_p2=length(id_AB_p2)
#####BA sequence, period 1
id_BA_p2=which(data$deltap2==0&data$seq=="ba")
num_missing_BA_p2=length(id_BA_p2)
#####function to resample coefficients and calculate mean
resample_p1<-function(model,b1){
cov=summary(model)$var
coef_all=summary(model)$table[,1]
##resample coef and scale(sigma) together from N
coef_all_new=rmvnorm(1,mean=coef_all,cov)
coef_hat_p1_new=coef_all_new[-length(coef_all_new)]
sd_hat_p1_new=exp(coef_all_new[length(coef_all_new)])
#get the mean for each person with censored data
mu_hat_BA_p1=coef_hat_p1_new[1]+coef_hat_p1_new[2]+b1*coef_hat_p1_new[3]
return(list(mu_hat_BA_p1,sd_hat_p1_new))
}
resample_p2<-function(model,b1_AB,p1_AB,b2_AB,b1_BA,p1_BA,b2_BA){
cov_p2=summary(model)$var
coef_all_p2=summary(model)$table[,1]
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##resample coef and scale(sigma) together from N
coef_all_p2_new=rmvnorm(1,mean=coef_all_p2,cov_p2)
coef_hat_p2_new=coef_all_p2_new[-length(coef_all_p2_new)]
sd_hat_p2_new=exp(coef_all_p2_new[length(coef_all_p2_new)])
#get the mean for each person with censored data
mu_hat_AB_p2=coef_hat_p2_new[1]+coef_hat_p2_new[2]+b1_AB*coef_hat_p2_new[3]+
p1_AB*coef_hat_p2_new[4]+b2_AB*coef_hat_p2_new[5]
mu_hat_BA_p2=coef_hat_p2_new[1]+b1_BA*coef_hat_p2_new[3]+
p1_BA*coef_hat_p2_new[4]+b2_BA*coef_hat_p2_new[5]
return(list(mu_hat_AB_p2,mu_hat_BA_p2,sd_hat_p2_new))
}
###impute from log-normal
impute_fn<-function(mu_hat,sd_hat){
lowerbd=pnorm((log(tau)-mu_hat)/sd_hat)
z_unif=sapply(lowerbd,function(x) runif(1,min=x))
imputed=mu_hat+qnorm(z_unif)*sd_hat
return(imputed)
}
#########################################
######Impute assuming log-normal#########
#########################################
#First, impute censored values in period 1
data$trt_ind=c(rep(0,20),rep(1,20))
model_p1=survreg(Surv(log(p1),deltap1,type=’right’)~trt_ind+log(b1),
dist=’gaussian’,robust=T,data=data)
out_ln_p1=resample_p1(model_p1,log(data$b1[data$id %in% id_BA_p1]))
mu_hat_BA_p1=out_ln_p1[[1]]
sd_hat_p1=out_ln_p1[[2]]
data$p1_imputed_ln=data$p1
data$deltap1_imputed=data$deltap1
####################################################
########Impute from Weibull########################
###################################################
#First, impute censored values in period 1
######censored in post-trt period 1
model_p1_weib=survreg(Surv(p1,deltap1,type=’right’)~trt_ind+b1,
dist=’weibull’,robust=T,data=data)
out_weib_p1=resample_p1(model_p1_weib,data$b1[data$id%in%id_BA_p1])
mu_hat_BA_p1_weib=out_weib_p1[[1]]
sd_hat_p1_weib=out_weib_p1[[2]]
data$p1_imputed_weib=data$p1
####impute m times
m=50
aic_ln_p=rep(NA,m)
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aic_weib_p=rep(NA,m)
beta_hat=rep(NA,m)
se_beta_hat=rep(NA,m)
beta_hat_log_weib=rep(NA,m)
se_beta_hat_log_weib=rep(NA,m)
for (j in 1:m){
#############################################
##########log-normal#########################
#############################################
####First, impute censored values in period 1
data$p1_imputed_ln[id_BA_p1]=exp(impute_fn(mu_hat_BA_p1,sd_hat_p1))
data$deltap1_imputed[id_BA_p1]=1
####Second,impute censored values in period 2
data$trt_ind_p2=c(rep(1,20),rep(0,20))
model_p2_censored=survreg(Surv(log(p2),deltap2,type=’right’)~trt_ind_p2
+log(b1)+log(p1_imputed_ln)
+log(b2),dist=’gaussian’,robust=T,data=data)
out_ln_p2=resample_p2(model=model_p2_censored,
b1_AB=log(data$b1[data$id%in%id_AB_p2]),
p1_AB=log(data$p1_imputed_ln[data$id%in%id_AB_p2]),
b2_AB=log(data$b2[data$id%in%id_AB_p2]),
b1_BA=log(data$b1[data$id%in%id_BA_p2]),
p1_BA=log(data$p1_imputed_ln[data$id %in% id_BA_p2]),
b2_BA=log(data$b2[data$id%in%id_BA_p2]))
mu_hat_AB_p2=out_ln_p2[[1]]
mu_hat_BA_p2=out_ln_p2[[2]]
sd_hat_p2=out_ln_p2[[3]]
data$p2_imputed_ln=data$p2
data$p2_imputed_ln[id_AB_p2]=exp(impute_fn(mu_hat_AB_p2,sd_hat_p2))
data$p2_imputed_ln[id_BA_p2]=exp(impute_fn(mu_hat_BA_p2,sd_hat_p2))
######ANCOVA###########################
logy=log(data$p1_imputed_ln)-log(data$p2_imputed_ln)
logx=log(data$b1)-log(data$b2)
model=lm(logy~logx+as.numeric(data$seq=="ab"))
aic_ln_p[j]=AIC(model)
beta_hat[j]=-coef(model)[3]/2
se_beta_hat[j]=coef(summary(model))[3,2]/2
#############################################
##########Weibull############################
#############################################
############First, impute censored values in period 1
data$p1_imputed_weib[id_BA_p1]=sapply(exp(mu_hat_BA_p1_weib),function(x)
rtrunc(1,spec="weibull",a=tau,shape=1/sd_hat_p1_weib,scale=x))
####Second, impute censored values in period 2
model_p2_censored_weib=survreg(Surv(p2,deltap2,type=’right’)~trt_ind_p2+b1
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+p1_imputed_weib+b2,
dist=’weibull’,robust=T,data=data)
out_weib_p2=resample_p2(model=model_p2_censored_weib,
b1_AB=data$b1[data$id%in%id_AB_p2],
p1_AB=data$p1_imputed_weib[data$id%in%id_AB_p2],
b2_AB=data$b2[data$id%in%id_AB_p2],
b1_BA=data$b1[data$id%in%id_BA_p2],
p1_BA=data$p1_imputed_weib[data$id %in% id_BA_p2],
b2_BA=data$b2[data$id%in%id_BA_p2])
mu_hat_AB_p2_weib=out_weib_p2[[1]]
mu_hat_BA_p2_weib=out_weib_p2[[2]]
sd_hat_p2_weib=out_weib_p2[[3]]
data$p2_imputed_weib=data$p2
data$p2_imputed_weib[id_AB_p2]=sapply(exp(mu_hat_AB_p2_weib),function(x)
rtrunc(1,spec="weibull",a=tau,shape=1/sd_hat_p2_weib,scale=x))
data$p2_imputed_weib[id_BA_p2]=sapply(exp(mu_hat_BA_p2_weib),function(x)
rtrunc(1,spec="weibull",a=tau,shape=1/sd_hat_p2_weib,scale=x))
######ANCOVA###########################
logy_weib=log(data$p1_imputed_weib)-log(data$p2_imputed_weib)
logx_weib=log(data$b1)-log(data$b2)
model_log_weib=lm(logy_weib~logx_weib+as.numeric(data$seq=="ab"))
aic_weib_p[j]=AIC(model_log_weib)
beta_hat_log_weib[j]=-coef(model_log_weib)[3]/2
se_beta_hat_log_weib[j]=coef(summary(model_log_weib))[3,2]/2
}
#####################################################
#######Combine the beta’s from model averaging ######
#####################################################
w_lognormal_p=exp(-aic_ln_p/2)/(exp(-aic_ln_p/2)+exp(-aic_weib_p/2))
w_weib_p=exp(-aic_weib_p/2)/(exp(-aic_ln_p/2)+exp(-aic_weib_p/2))
beta_hat_log_combined=beta_hat*w_lognormal_p+beta_hat_log_weib*w_weib_p
####Within imputation variance from model averaging
var_ln=rep(NA,m)
var_weib=rep(NA,m)
for(j in 1:m){
var_ln[j]=w_lognormal_p[j]*sqrt(se_beta_hat[j]^2+(beta_hat[j]
-beta_hat_log_combined[j])^2)
var_weib[j]=w_weib_p[j]*sqrt(se_beta_hat_log_weib[j]^2
+(beta_hat_log_weib[j]-beta_hat_log_combined[j])^2)
}
####combine beta across multiple imputation
beta_hat_mean=mean(beta_hat_log_combined)
###calculate p-value
within_imp_var=mean((var_ln+var_weib)^2)
btw_imp_var=sum((beta_hat-beta_hat_mean)^2)/(m-1)
total_var=within_imp_var+(1+1/m)*btw_imp_var
gamma=(1+1/m)*btw_imp_var/total_var
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dof_com=mean(n-num_missing_p1,n-num_missing_p2)-3
##degrees of freedom
dm=(m-1)*(1+within_imp_var/((1+1/m)*btw_imp_var))^2
##degrees of freedom for small samples
dof=(1-gamma)*((dof_com+1)/(dof_com+3))*dof_com
ts=abs(beta_hat_mean/sqrt(total_var))
dof_obs=(1-gamma)*((dof_com+1)/(dof_com+3))*dof_com
dof=1/(1/dof_obs+1/dm)
###Point estimate
exp(beta_hat_mean)
##P-value
pval_base=2*(1-pt(ts,df=dof))
##CI
exp(c(beta_hat_mean-qt(0.975,df=dof)*sqrt(total_var),
beta_hat_mean+qt(0.975,df=dof)*sqrt(total_var)))
68
APPENDIX B
SUPPLEMENTARY MATERIALS FOR CHAPTER 3
B.1. Two Approaches for Nuisance Parameters Estimation for the RGLR Statistic
We show here the details of the calculation for nuisance parameter in RGLR statistic using two
different approaches: MLE from the likelihood of two Binomials, and inverse-variance weighted
average.
B.1.1. MLE from Likelihood
We have two Binomial distributions for the number of events in group A and group B, namely diB ∼
Binomial (RiB , piiB), where piiB = 1− e−pi , and diA ∼ Binomial (RiA, piiA), where piiA = 1− e−θpi .
Then, the likelihood from the two Binomial is
L = pidiAiA (1− piiA)RiA−diApidiBiB (1− piiB)RiB−diB
= (1− e−θpi)diA(e−θpi)RiA−diA(1− e−pi)diB (e−pi)RiB−diB
Take the log of the likelihood, we have
l = diA log(1− e−θpi)− θpi(RiA − diA) + diB log(1− e−pi)− pi(RiB − diB)
Take derivative with respect to pi,
∂l/∂pi =
diAθe
−θpi
1− e−θpi − θ(RiA − diA) +
diBe
−pi
1− e−pi − (RiB − diB) = 0 (B.1)
Because there is only one person having an event at any time ti, i.e., diA = 0, diB = 1 or
diB = 0, diA = 1, we can use this to simplify the equation above to solve for pi.
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Case1: When diA = 0, diB = 1, equation (B.1) becomes
−θRiA + e
−pi
1− e−pi − (RiB − 1) = 0
(1− e−pi)(−θRiA −RiB + 1) + e−pi = 0
e−pi(θRiA +RiB) = θRiA +RiB − 1
pi = log
(
θRiA +RiB
θRiA +RiB − 1
)
Case2: When diB = 0, diA = 1, equation (B.1) becomes
θe−θpi
1− e−θpi − θ(RiA − 1)−RiB = 0
θ
eθpi − 1 − θ(RiA − 1)−RiB = 0
pi = log
(
θRiA +RiB
θRiA +RiB − θ
)
B.1.2. Inverse-Variance Weighting
Again, we have two Binomial distributions, diB ∼ Binomial (RiB , piiB), where piiB = 1 − e−pi , and
diA ∼ Binomial (RiA, piiA), where piiA = 1 − e−θpi . Then, naturally, we have 2 point estimates for
the nuisance parameter pi from the two Binomial distributions:
pˆiB = − log
(
1− diBRiB
)
, and pˆiA = − 1θ log
(
1− diARiA
)
We also know that Var(diB) = RiBpiiB(1 − piiB) and Var(diA) = RiApiiA(1 − piiA), so we can take
the average of the 2 point estimates weighted by inverse-variance.
To compute the variance for pˆiB , by definition, we have
Var(pˆiB) = Var
[
− log
(
1− diB
RiB
)]
= E
[{
− log
(
1− diB
RiB
)}2]
−
{
E
[
− log
(
1− diB
RiB
)]}2
The formula for the two expectations seem very complex, but we can simplify and approximate
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them using the assumption of no tied observations. By definition,
E
[
− log
(
1− diB
RiB
)]
(B.2)
= − log
(
1− 0
RiB
)
· P (diB = 0)− log
(
1− 1
RiB
)
· P (diB = 1) (B.3)
− log
(
1− 2
RiB
)
· P (diB = 2)− · · · − log
(
1− RiB
RiB
)
· P (diB = RiB) (B.4)
Because diB can only be 0 or 1, we can think of the probability of diB > 1 to be very close to 0 and
thus get rid of the cases where diB > 1. Thus, equation (B.2) can be approximated by
E
[
− log
(
1− diB
RiB
)]
≈ 0− log
(
1− 1
RiB
)
· P (diB = 1) (B.5)
= − log
(
1− 1
RiB
)
RiBpiiB(1− piiB)RiB−1 (B.6)
≈ − log
(
1− 1
RiB
)
RiBpiiB (B.7)
Again, given that the probability mass is mainly on 0 and 1, piiB should be close to 0, and thus we
can approximate (1− piiB) to be 1 and simplify equation B.6 to B.7.
Similarly, we have
E
[{
− log
(
1− diB
RiB
)}2]
≈
[
log
(
1− 1
RiB
)]2
RiBpiiB
Therefore,
Var(pˆiB) =
[
log
(
1− 1
RiB
)]2
RiBpiiB(1−RiBpiiB)
=
[
log
(
1− 1
RiB
)]2
RiB(1− e−pi)[1−RiB(1− e−pi)]
Follow a similar logic, we can derive the variance of pˆiA
Var(pˆiA) =
[
log
(
1− 1
RiA
)]2
RiApiiA(1−RiApiiA)
=
[
log
(
1− 1
RiA
)]2
RiA(1− e−θpi)[1−RiA(1− e−θpi)]
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Now, use the inverse-variance weighting, and equate the true pi to the average,
pi =
pˆiB
Var(pˆiB)
+ pˆiAVar(pˆiA)
1
Var(pˆiB)
+ 1Var(pˆiA)
pi =
pˆiBVar(pˆiA) + pˆiAVar(pˆiB)
Var(pˆiB) + Var(pˆiA)
Use the fact that there is only one event at each time point to simplify the equation,
Case1: When diB = 0, diA = 1, pˆiB = − log(1− 0) = 0,
pi =
pˆiAVar(pˆiB)
Var(pˆiB) + Var(pˆiA)
(B.8)
pi[Var(pˆiB) + Var(pˆiA)] (B.9)
= −1
θ
log
(
1− 1
RiA
)[
log
(
1− 1
RiB
)]2
RiB(1− e−pi)[1−RiB(1− e−pi)] (B.10)
The left-hand side of equation B.9 is a product of pi and function of e−pi and e−θpi , and the right-
hand side is a function of e−pi . On the other hand, the equation (1) from the likelihood is only a
function of e−pi and e−θpi .
Case2: When diB = 1, diA = 0, pˆiA = 0,
pi =
pˆiBVar(pˆiA)
Var(pˆiB) + Var(pˆiA)
(B.11)
pi[Var(pˆiB) + Var(pˆiA)] (B.12)
= − log
(
1− 1
RiB
)[
log
(
1− 1
RiA
)]2
RiA(1− e−θpi)[1−RiA(1− e−θpi)] (B.13)
Again, the left-hand side of equation B.12 involves both pi and function of e−pi and e−θpi , which
does not agree with equation (B.1).
For RGLR statistic, the inverse-variance weighting average and likelihood MLE approach generate
two different estimates for the nuisance parameters. The MLE approach is able to provide us a
closed-form under no ties assumption. However, the inverse-variance weighting average approach
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results in a somewhat complex form. Although we can still solve it through numerical solutions, it
will introduce approximation in the nuisance parameters. Therefore, we recommend using the MLE
approach to for nuisance parameter estimation for the RGLR statistic.
B.2. Supplementary Figure
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Figure B.1: Hazard function of Gompertz(shape=0.5, rate=0.2), Weibull(shape=2, rate=0.5) and
Exponential(rate=0.5).
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APPENDIX C
SUPPLEMENTARY MATERIALS FOR CHAPTER 4
C.1. Verification of the Variance Formula for the RGLR Estimator
To examine the accuracy of equation (4.11), we performed a simulation of 5000 replications with
varying β, sample size and percentage censoring. We generated group B survival data from a
Weibull distribution with shape parameter of 2 and scale parameter of 0.6; for group A, the Weibull
parameters were chosen to ensure a constant hazard ratio (A:B) over time, with β =0, -0.3, -0.8 and
-1.3. We studied sample sizes per group of 25, 50, 100, and 25% and 50% censoring. As shown
in Table C.1, the mean of the estimated variance Vˆ from using equation (4.11) was very close to
the empirical variance of βˆRGLR (i.e., the variance of the 5000 βˆRGLR values) for all simulated
scenarios, even when the sample size was as small as 25 subjects per group with 25% censoring.
This indicates that equation (4.11) is able to accurately estimate the true variance of βˆRGLR within
each stratum.
Table C.1: Comparison of the mean of the proposed variance estimator
for the log hazard ratio to the empirical variance based on data from
Weibull distribution and 5000 simulations.
N /trt β 25% Censoring 50% Censoring
Var(βˆRGLR) Mean of Vˆ Var(βˆRGLR) Mean of Vˆ
25 0 0.119 0.119 0.221 0.230
-0.3 0.122 0.122 0.174 0.177
-0.8 0.139 0.133 0.192 0.196
-1.3 0.163 0.159 0.239 0.227
50 0 0.056 0.057 0.106 0.107
-0.3 0.056 0.058 0.083 0.084
-0.8 0.066 0.063 0.092 0.091
-1.3 0.078 0.075 0.101 0.102
100 0 0.029 0.028 0.051 0.052
-0.3 0.028 0.029 0.039 0.041
-0.8 0.030 0.031 0.043 0.044
-1.3 0.037 0.036 0.050 0.049
Trt: treatment group. β: log hazard ratio. Var(βˆRGLR): empirical variance
of estimated log hazard ratio. Vˆ : proposed variance estimator for the refined
generalized log-rank statistic (RGLR) estimator for log hazard ratio in equa-
tion (4.11).
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